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RESUME 
Introduction: Les cellules T mémoires humaines sont classées en trois sous-populations sur 
la base de l'expression d'un marqueur de surface cellulaire, CD45RA, et du récepteur aux 
chimiokines, CCR7. Ces sous-populations, nommées cellules mémoires centrales (TcM), 
mémoires effectrices (T EM) et mémoires effectrices terminales (T TEM), ont des rôles 
fonctionnels distincts, ainsi que des capacités de prolifération et de régénération différentes. 
Cependant, la génération des ces différences reste encore mal comprise et on ignore les 
mécanismes moléculaires impliqués. 
Matériaux et Méthodes: Des cellules mononucléaires humaines du sang périphérique ont été 
séparées par cytométrie de flux selon leur expression de CD4, CD8, CD45RA et CCR7 en 
sous-populations de cellules CD4+ ou CD8+ naïves, T cM, T EM ou T TEM· Dans chacune des ces 
sous-populations, 14 gènes impliqués dans l'apoptose, la survie ou la capacité proliférative 
des cellules T ont été quantifiés par RT-PCR en temps réel, relativement à l'expression d'un 
gène de référence endogène. L' ARN provenant de 450 cellules T a été utilisé par gène et par 
sous-population. Les gènes analysés (cibles) comprenaient des gènes de survie (BAFF, 
APRIL, BAFF-R, BCMA, TACI, IL-15Ra, IL-7Ra), des gènes anti-apoptotiques (Bcl-2, Bcl-
xL, FLIP), des gènes pro-apoptotiques (Bad, Bax, FasL) et le gène anti-prolifératif, Tob. A 
l'aide de la méthode comparative delta-delta-CT, le taux d'expression des gènes cibles de 
chaque sous-population des cellules T mémoires CD4+ et CD8+, à été comparée à leur taux 
d'expression dans les cellules T naïves CD4+ et CD8+. 
Résultats: Dans les cellules CDS+, les gènes pro-apoptotiques Bax et FasL étaient 
surexprimés dans toutes les sous-populations mémoires, tandis que l'expression des facteurs 
anti-apoptotiques et de survie comme Bcl-2, APRIL et BAFF-R, étaient diminués. Ces deux 
tendances étaient particulièrement accentuées dans les sous-groupes des cellules mémoires 
T EM et T TEM· A noter que malgré le fait que leur expression était également diminuée dans les 
autres cellules mémoires, le facteur de survie IL-7Ra, était sélectivement surexprimé dans la 
sous-population de cellules T cM et l'expression d'IL-15Ra était sélectivement augmentée dans 
les TEM· Dans les cellules CD4+, le taux d'expression des gènes analysés était plus variable 
entre les sujets étudiés que dans les cellules CD8+, ne permettant pas de définir un profil 
d'expression spécifique. L'expression du gène de survie BAFF par contre, a été 
significativement augmentée dans toutes les sous-populations mémoire CD4+. Il en va de 
même pour l'expression d' APRIL et de BAFF-R, bien que dans moindre degré. A remarquer 
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que l'expression du facteur anti-apoptotique FasL a été observé uniquement dans la sous-
population des T TEM· 
Discussion et Conclusions: Cette étude montre une nette différence entre les cellules CD8+ et 
CD4+, en ce qui concerne les profils d'expression des gènes impliqués dans la survie et 
l'apoptose des cellules T mémoires. Ceci pourrait impliquer une régulation cellulaire 
homéostatique distincte dans ces deux compartiments de cellules T mémoires. Dans les 
cellules CD8+ l'expression d'un nombre de gènes impliqués dans la survie et la protection de 
l'apoptose semblerait être diminuée dans les populations T EM et T TEM en comparaison à celle 
des sous-populations naïves et T cM, tandis que l'expression des gènes pro-apoptotiques 
semblerait être augmentée. Comme ceci paraît être plus accentué dans les T TEM, cela pourrait 
indiquer une plus grande disposition à l'apopotose dans les populations CCRT (effectrices) et 
une perte de survie parallèlement à l'acquisition de capacités effectrices. Ceci parlerait en 
faveur d'un modèle de différentiation linéaire dans les cellules CD8+. De plus, l'augmentation 
sélective de l'expression d'IL-7Ra observée dans le sous-groupe de cellules mémoires T cM, et 
d 'IL- l 5Ra dans celui des T EM, pourrait indiquer un moyen de sélection pour des réponses 
immunitaires mémoires à long terme par une réponse distincte à ces cytokines. Dans les 
cellules CD4+ par contre, aucun profil d'expression n'a pu être déterminé; les résultats 
suggèrent même une résistance relative à l'apoptose de la part des cellules mémoires. Ceci 
pourrait favoriser l'existence d'un modèle de différentiation plus flexible avec des possibilités 
d'interaction multiples. Ainsi, la surexpression sélective de BAFF, APRIL et BAFF-R dans 
les sous-populations individuelles des cellules mémoires pourrait être un indice de 
l'interaction de ces sous-groupes avec des cellules B. 
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ABSTRACT 
Introduction: Based on their surface expression of the CD45 isoform and of the CCR 7 
chemokine receptor, memory T cells have been divided into the following three subsets: 
central memory (T cM), effector memory (T EM) and terminal effector memory (T TEM). Distinct 
functional roles and different proliferative and regenerative capacities have been attributed to 
each one of these subpopulations. The molecular mechanisms underlying these differences, 
however, remain poorly understood. 
Materials and Methods: According to their expression of CD4, CDS, CD45RA and CCR7, 
human peripheral blood mononuclear cells were sorted by flow-cytometry into CD4+ or CDS+ 
naïve, TcM, TEM and TTEM subsets. Using real-time PCR, the expression of 14 genes known to 
be involved in apoptosis, survival or proliferation of T cells was quantified separately in each 
individual subset, relative to an endogenous reference gene. The RNA equivalent of 450 T 
cells was used for each gene and subset. The target gene panel included the survival genes 
BAFF, APRIL, BAFF-R, BCMA, TACI, IL-15Ra and IL-7Ra, the anti-apoptotic genes Bcl-
2, Bcl-xL and FLIP, the pro-apoptotic genes Bad, Bax and FasL, as well as the anti-
proliferative gene Tob. Using the comparative CT-method, the expression of the target genes 
in the three memory T cell subsets of both CD4+ and CDS+ T cell populations was compared 
to their expression in the naïve T cells. 
Results: In CD8+ cells, the pro-apoptotic factors Bax and FasL were found to be upregulated 
in all memory T cell subsets, whereas the survival and anti-apoptotic factors Bcl-2, APRIL 
and BAFF-R were downregulated. These tendencies were most accentuated in TEM and TTEM 
subsets. Even though the survival factor IL-7Ra was also downregulated in these subsets, 
interestingly, it was selectively upregulated in the CDS+ T CM subset. Similarly, IL-l 5Ra-
expression was shown to be selectively upregulated in the CDS+ T EM subset. In CD4+ cells, 
the expression levels of the analyzed genes showed a greater inter-individual variability than 
in CDS+ cells, thus suggesting the absence of any particular expression pattern for CD4+ 
memory T cells. However, the survival factor BAFF was found to be significantly upregulated 
in all CD4+ memory T cell subsets, as was also the expression of APRIL and BAFF-R, 
although to a lesser extent. Furthermore, it was noted that the pro-apoptotic gene FasL was 
only expressed in the T TEM CD4+ subset. 
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Discussion and Conclusions: Genes involved in apoptosis and survival in human memory T 
cells have been shown to be expressed differently in CDS+ cells as compared to CD4+ cells, 
suggesting a distinct regulation of cell homeostasis in these two memory T cell compartments. 
The present study suggests that, in CDS+ T cells, the expression of various survival and anti-
apoptotic genes is downregulated in T EM and T TEM subsets, while the expression of pro-
apoptotic genes is upregulated in comparison to the naïve and the T CM populations. These 
characteristics, potentially translating to a greater susceptibility to apoptosis in the CCR T 
( effector) memory populations, are accentuated in the T TEM population, suggesting a loss of 
survival in parallel to the acquisition of effector capacities. This speaks in favour of a linear 
differentiation model in CDS+ T memory cells. Moreover, the observed selectively increased 
expression of IL-7Ra in CDS+ T CM cells - as that of IL-15Ra in CDS+ T EM cells - suggest that 
differential responsiveness to cytokines could confer a selection bias for distinct long-term 
memmy cell responses. Relative to the results for CDS+ T cells, those for CD4+ T cells seem 
to indicate a certain resistance of the memory subsets to apoptosis, suggesting the possibility 
of a more flexible differentiation model with multiple checkpoints and potential interaction of 
CD4+ memmy cells with other cells. Thus, the selective upregulation of BAFF, APRIL and 
BAFF-R in individual memory subsets could imply an interaction of these subsets with B 
cells. 
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General Introduction 
1 GENERALINTRODUCTION 
1.1 THE IMMUNE SYSTEM 
Humans and other organisms depend on their immune system to fight disease. 1-3 This is 
especially true when they are confronted with infection, caused by invasion of 
microorganisms such as bacteria, virus, fungi and parasites. Qualitatively, the immune system 
can be divided into two large entities - the innate immune system and the acquired immune 
system. The innate immune system mediates a non-specific response against a pathogen, and 
its efficiency does not depend upon the amount of times the organism encounters the 
pathogen. Its main components are the complement system, which consists of serum proteins 
and macrophages, phagocytes and natural killer (NK) cells, which destroy the pathogen or 
infected cells. The acquired immune system, on the other hand, mounts an immune response, 
which is highly specific to the pathogen that it was elicited by. Moreover, the acquired 
immune system possesses an adaptive quality ensuring that, once the organism has survived 
an initial infection by a pathogen, it will generally present a more efficient defense and 
consequently be immune to further illness caused by that same pathogen. 
In reality, this separation is not very accurate, and there are many cases where the innate and 
the acquired immune systems are intertwined. The protective action of the immune system, as 
a whole, depends on a variety of soluble factors (humoral immune response) and different 
types of white blood cells or leucocytes that are produced in the bone marrow (cellular 
immune response). In the acquired immune system, both these lines of defense are mostly 
based on the action of either B or T lymphocytes, which are subclasses of leucocytes. The 
acquired humoral immune system depends primarily on B lymphocytes that mature into 
plasma cells and produce soluble proteins called antibodies or immunoglobulins (lg). 
Antibodies are highly pathogen-specific and act against extracellular microorganisms in the 
blood which are mostly bacteria. The acquired cellular immune system is mainly based on 
the action of different subtypes of T lymphocytes, such as regulatory T cells, helper T cells 
and cytolytic T cells (CTLs). One of its major fonctions is the destruction of cells invaded by 
intracellular pathogens such as viruses, but it also acts against other altered cells like tumor 
cells. The two systems coordinate with each other, thanks to helper T cells which provide 
important maturation signais to B lymphocytes. 
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1.2 T CELL MEDIATED IMMUNITY 
Like B cells, T lymphocytes are also produced in the bone marrow; their maturation however, 
takes place in the thymus. They can be divided into many subpopulations according to their 
expression of surface antigens, which are called cluster of differentiation (CD) and have been 
classified by numbers. The two main categories of T cells are CD4+ cells (also called helper T 
cells) and CDS+ T cells (also called cytolytic T cells or CTLs). 1-3 
From the bone malTow, T cells migrate to the thymus where they mature from double positive 
(DP), CD8+CD4+ cells into single positive CD8+ or CD4+ cells. In parallel, they acquire 
specific T cell receptors (TCRs) which they express on their surface. Diverse TCRs are 
produced through a complex genetic rearrangement, so that in the end each T cell is unique 
and specific to a certain antigen. A selection process in the thymus ensures that self-reactive T 
cells and ineffective T cells are destroyed (positive and negative selection). From the thymus, 
T cells enter the bloodstream and recirculate between blood and secondaiy lymphoid organs. 
Secondary lymphoid organs include tonsils, lymph nodes, spleen and mucosa-associated 
lymphoid tissue (MALT), such as Peyer's patches of the gut (Figure 1.1). Even though these 
T cells are mature, they are known as naïve T cells, because they have not yet encountered 
their antigen. The migration of naïve T cells into lymphoid tissues is mediated by 
chemokines, such as secondary lymphoid tissue chemokine (SLC), EB 1 ligand chemokine 
(ELC) and addressins like PNAd.4 The lymph-homing chemokine receptor CCR7, expressed 
on naïve T cells (but also on a subset of memory T cells), binds to SLC which is expressed by 
the high vascular endothelium (HEV), stromal cells and dendritic cells in lymphoid tissue. In 
this manner, CCR7 mediates T cell entry to lymph nodes (Figure 1.1). 
When there is infection, pathogens or their products are transported from the target organ to 
the lymphoid tissue by draining lymphatics or, more rarely, directly by the blood. Adaptive 
immune responses are therefore not initiated at the infection site, but rather in the organized 
peripheral lymphoid tissue, through which naïve T cells are continuously migrating. In order 
to initiate an adaptive immune response, T cells need to first recognize an infected cell and 
then eliminate it, by either killing it directly or indirectly through activation of macrophages 
and B cells. This is possible through a coordinated interaction between professional antigen-
2 
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FIGURE 1.1 Physiological recirculation of T lymphocytes 
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T lymphocytes (Le) are produced in the bone marrow (BM) and then migrate to the thymus (T), where they 
mature. Mature naïve T cells recirculate through blood (red fines) and lymphatic vessels 61ellow fines). They 
express the chemokine receptor CCR7, which enables them to internet with the secondary lymphoid tissue 
chemokine (SLC). SLC is expressed on the high endothelial venules (HEV) of secondary lymphoid organs, such 
as tonsils (To ), lymph nodes (LN), spleen (SP) and mucosa-associated lymphoid tissue (MALT). T cells either 
re-enter the blood stream through the thoracic duct (TD) or leave the lymphatic circulation through the HEV 
once they have been activated by antigen encounter in a draining lymph node. Activated T cells (aLc) lose their 
expression of CCR7 and express other chemokine receptors, enabling them to migrate to target organs (ORO) 
such as the lung, liver and skin. Primary lymphoid organs are shown in green; secondmy lymphoid organs are 
shown in yellow. 
presenting cells (APCs), located in the secondary lymphoid tissues or in peripheral target 
organs, cytotoxic T cells (CTLs or CD8+ T lymphocytes) and helper T cells (CD4+ T 
lymphocytes). T cells encounter the pathogen products (antigen) by the help of APC, which 
carry different antigens in the form of peptide-MHC complexes on their surface. The most 
important APCs are dendritic cells (DCs) which are specialized in trapping antigen at the site 
of infection and migrating to a downstream lymph node. Once the antigen has been captured 
by the DC, it triggers a maturation process which results in the expression of co-stimulatory 
factors that are required, in addition to the antigen, for the activation of naïve T cells. 
Activated T cells lose the expression of CCR 7 and instead express inflammation-specific 
receptors, such as CCRl, 2, 3, 4, 5 and CXCR3. These receptors bind to adhesion molecules, 
such as ICAM-1, VCAM-1, E-and P-selectins expressed on blood vessels and inflamed 
tissues.5•6 This interaction enables the activated T cell to be recruited to the infection site 
(Figure 1.1). 
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The antigen-specific clonal expansion of naïve T cells requires a second or co-stimulatory 
signal, which must be delivered by the same antigen-presenting cell on which T cells 
recognize the antigen. The best characterized co-stimulatory molecules are the structurally 
related glycoproteins B7.1 (CD80) and B7.2 (CD86), which are homodimeric members of the 
immunoglobulin superfamily and are exclusively found on the surface of cells that can 
stimulate T-cell proliferation. The receptors for B7 molecules on T cells are CD28 and the 
cytotoxic T lymphocyte antigen 4 (CTLA-4). In vitro, an unspecific but efficient TCR-
triggered response can be obtained by stimulating T cells with anti-CD3 antibodies (which 
bind to the TCR-associated molecule CD3) and anti-CD28 monoclonal antibodies. Interaction 
of CD28 with B7 molecules, or alternatively with anti-CD28 antibodies used in experimental 
conditions, co-stimulates the activation signal given to the naïve T cell by its TCR. This leads 
to a clonal expansion of the activated T cell. Antigen binding to the TCR in the absence of 
co-stimulation, not only fails to activate T cells, but even leads to a dysfunctional state termed 
anergy. Anergie T cells are refractory to activation by a specific antigen, even when the 
antigen is subsequently presented by an APC. 
1.3 IMMUNOLOGICAL MEMORY 
Immunological memory results in a faster and stronger immune response of an organism, 
following reexposure to the same antigen. In general, it leads to a better protection against an 
invading pathogen. 7 In what ways does this memory response differ from the primary 
response, so as to have a protective advantage over the latter? 
In the case of the humoral response, these advantages are clearly identifiable. Not only is 
there a greater frequency of specific antigen reactive cells, the quality of the memory cells is 
also notably different from that of naïve B cells. The pathway of the memory B cell 
development occurs in the germinal centers of peripheral lymph nodes and involves isotype 
switching and hypermutation of immunoglobulin genes, allowing memory B cells to be easily 
identified. T cell memory is more difficult to define. No anatomical site has been identified 
where memory T cells develop, and there is no isotype switching or affinity-selected mutation 
of the TCR, making the identification of memory T cells difficult. 7 Thus, man y aspects of T 
cell memory still remain an issue of debate. However, one can implicate three major 
mechanisms, leading to a greater protection of the organism during the memory response. 
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Firstly, clonal selection and expansion lead to increased numbers of antigen-specific cells, 
making it one of the earliest explanations8 of the higher efficiency of the memory T cell 
response. A particular antigen will drive the expansion of the T cell with the most specific 
TCR, inducing it to clone itself - thus creating greater frequencies of highly antigen-specific 
cells. Due to this phenomenon, during the first days to weeks following exposure to a 
pathogen, there is an extensive expansion of antigen-specific T cells. Ideally this will 
culminate in the elimination of the pathogen. Then, however, follows a phase of contraction, 
during which the majority of the activated effector cells undergo apoptosis. Even so, the end 
result is a net increase in the numbers of pathogen-specific memory T cells,9 and reencounter 
with the same antigen expands the population to a new, stable higher level (Figure 1.2). 
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FIGURE 1.2 Phases of the immunological response in T-cell mediated immunity 
Primary infection results in the clonal expansion of antigen-specific T cells that will eventually lead to 
eradication of the pathogen. Within a few weeks, the majority of the expanded effector T cells undergo apoptosis 
and the population of specific cells contracts. The surviving T cells develop into memory cells that can be 
maintained at constant levels for years in the absence of pathogen. Thus, even though these specific memory T 
cells represent just a fraction of the initially expanded effector population, their formation results in a net 
increase of antigen-specific cells after pathogen clearance. Besides, by being more efficient in the control of 
pathogen, this memory T cell population ensures a faster immune response upon re-infection, resulting in the 
absence or attenuation of disease. (Figure adapted fiwn Antia R et al) .10 
Secondly, memory cells are more easily triggered than naïve cells, responding at lower 
antigen dose and with less stringent requirements for co-stimulation.7 This results in a lower 
activation threshold and ensures higher and faster responsiveness to antigen. Finally, memory 
5 
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cells can persist as non-dividing cells in the absence of antigen stimulation over extended 
periods of time. 10 The combination of these characteristic features are thought to be the basis 
of a more rapid and efficient immune response upon reexposure, which results in an enhanced 
protection from disease for the organism. 
1.4 MEMORY T CELLS 
As mentioned above, the development of T cell memory is complex and even though memory 
T cells are different from naïve cells, various criteria have to be combined in order to identify 
them. Firstly, memory T cells express activation markers and cell surface receptors distinct to 
those of naïve cells. Secondly, memory T cells can be distinguished by their capacity to 
secrete a wider range of cytokines. Notably, they can also be polarized to perform unique 
functions specified by the pattern of cytokines they secrete. On the basis of these 
characteristics, recent research bas led to the development of different models of T cell 
memory, emphasizing the existence of distinct subpopulations within memory T cells. Their 
identification is based on: 
• Phenotype, characterized by differential expression pattern of cell surface markers. 
• Effector functions, such as cytokine secretion and cytotoxic potential. 
The most widely used marker to distinguish between naïve and memory T lymphocytes in 
humans, is the CD45R isoform expressed on the cell surface in various combinations.7 
CD45R is a transmembrane phosphatase that regulates signaling through the TCR-CD3 
complex. Distinct isoforms are generated by alternative splicing of amino-terminal A, B and 
C exons. The high-molecular-weight protein (CD45RA) contains A and B and/or C exons, 
whereas the low-molecular-weight protein (CD45RO) does not contain any of the variable 
exons. T-cell activation induces a shift from expression of CD45RA to CD45RO. Thus, 
human naïve T cells are defined as CD45RA+ and CD45RO-. In contrast, human memory T 
cells express CD45RO and mostly lack CD45RA. However, memory T lymphocytes are a 
heterogeneous group of cells, and it bas been shown that some subgroups of memory T cells 
reexpress CD45RA. 11 
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Another marker, now increasingly used, is the chemokine receptor CCR7. CCR7 enables T 
cells to leave the bloodstream and enter into lymphoid tissue via its interaction with SLC 
(Secondary Lymphoid tissue Chemokine). Thus, the advantage of this marker is not only in 
defining naïve and memory subsets, but also in that it enables a fonctional characterization. 
Most importantly, CCR7 has been found to define distinct subsets12 of memory cells within 
the population of total memory T cells, depending on their homing and effector capacities: 
• CCR 7 - T cells express receptors for migration into inflamed tissues. Upon re-
encounter with antigen, they can rapidly produce IFN-.. f or IL-4 or release pre-stored 
perforin, thus mediating immediate protection by cytotoxicity. 
• CCR 7 + T cells home to secondary lymphoid organs such as lymph nodes and may 
have a high proliferative potential. However, they lack immediate effector fonctions 
such as cytokine secretion and cytotoxicity. 
Using the markers CCR7 and CD45RA for flow cytometric studies, Sallusto and colleagues 
identified four subpopulations of CD4 memory T cells. 12 They established a lineage pattern 
for CD4+ T cells by demonstrating a progressive differentiation from naïve to central 
memmy, to effector memory T cells (Figure 1.3). In their model, CD45RA+ CCR7+ T cells 
figure as precursors for the other subsets. They expand on antigen re-encounter to ensure 
continuous replenishment of the effector cell pools. CD45RA- CCR 7+ T cells are referred to as 
central memory T cells and have been shown to secrete smaller amounts of effector cytokines 
upon stimulation. One could thus imagine that they would not mediate effector-cell fonctions 
during the primary T cell response, but rather, serve as a reservoir, giving rise to secondary 
effector T cells upon antigen re-encounter. 13 CD45RA- CCRT T cells, on the other hand, 
rapidly secrete effector cytokines upon restimulation with antigen. They are termed pre-
terminally differentiated or effector memory T cells. The fourth subset reexpresses CD45RA 
and also homes to lymph nodes. Even though present in very small numbers in healthy 
individuals, this subset increases in response to chronic infection such as non-treated HIV 
infection. 14 
An analog model has been suggested for CDS+ T cells. In CDS+ T cells, the CD45RA+ CCRT 
cells were shown to rapidly secrete IFN-y upon restimulation and presented the highest levels 
of perforin expression. They are ready to intervene immediately following antigen re-
exposure and have accordingly been referred to as terminally differentiated memmy T cells. 11 
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FIGURE 1.3 Lineage pattern of memory T cells (as proposed by Sallusto and Lanzavecchia 11) 
Naïve T cells are CD45RA+ CCR7 + and fonction as precursors for different subtypes of memory T cells. 
CD45RA - CCR7 + or Central Memory T cells (CM) do not have direct effector function and serve as a 
reservoir for secondary effector cells upon re-exposure. CD45RA- CCR7 - Effector Memory T cells (EM) are 
pre-terminally differentiated effector cells that will either develop into terminally differentiated effector cells or 
be directly used against antigen when re-exposure occurs. CD45RA + CCR7 - or Terminal Effector Memory T 
cells (TEM) are the most potent secondary effector cells and intervene rapidly upon re-encounter. Dashed 
arrows indicate that CD45RA- CCR7 - (EM) cells may revert to CD45RA- CCR7 +(CM), or even to a naïve 
(CD45RA + CCR 7 +) phenotype, upon antigen stimulation. 
A functional implication of this model for memory T cell differentiation (Figure 1.3) would 
be an increased differentiation capacity and proliferation potential of the CD45RA- CCR 7 + 
(CM) cell population, as compared to the CD45RA- CCR 7 - (EM) and the CD45RA + CCR 7 -
(TEM) populations. This would enable the central memory subset to act as a reservoir for the 
effector memory T cell subsets. The latter, on the other hand, being at a more advanced state 
of differentiation should logically be more prone to cell death. Consequently, a linear loss of 
cell survival capacity and increase of cell death susceptibility from CM to TEM subsets could 
be indirect confirmations of the aforementioned differentiation model. 
1.5 APOPTOSIS AND SURVIVAL 
An organism is obliged to tightly regulate the balance of cell survival and cell death to 
maintain its structure and function. It is well known that the loss cell death control often leads 
to the formation of aberrantly long-lived, cancerous, cells - potentially dangerous for the 
organism. On the other hand, the positive side of the balance, survival, is important to allow 
correct development and differentiation of cells. This is crucial for the functional maturity of 
the organism. It is therefore not surprising that several pathways and genes have been found 
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to be implicated in the control of this balance. 15-22 Fundamentally, one can differentiate 
between two mechanisms of cell death. Necrosis23'24 normally results from a severe cellular 
insult and causes organelle swelling and loss of plasma membrane integrity. Apoptosis,25•26 on 
the other hand, is a programmed form of cell death, causing typical morphological changes in 
the cell in absence of an inflammatory response (apoptotic bodies). 
Since immune responses are often characterized by large clonal expansions, the immune 
system is particularly vulnerable to the consequences of unchecked proliferation, such as 
autoimmunity and malignancy.27 Apoptosis is a critical regulator of homeostasis in the 
immune system and permits to maintain constant cell numbers, once the antigenic stimulus 
has been cleared, thus avoiding the accumulation of a large number of cells. It is a complex, 
multifactorial process, tightly regulated by many genes and can be induced in two different 
pathways: 
111 The extrinsic pathway depends on external signais from death activators binding to 
receptors at the cell surface. 
111 The intrinsic pathway is initiated by death signais arising within the cell. 
1.5.1 The extrinsic (death receptor) pathway 
The extrinsic pathway28-30 is induced by triggering death-receptors, all members of the TNF-
receptor protein superfamily. The most important of these interactions is the binding of Fas to 
its ligand Fas ligand (FasL) (Figure 1.4, A). 
FasL is a transmembrane protein belonging to the TNF family and binds to its receptor Fas, 
which is an integral membrane protein with its receptor domain exposed at the surface of the 
cell. The interaction results in clustering of the death-receptor Fas on the cell surface and 
recruitment of the Fas-associated death domain protein (F ADD), leading to the formation of 
the death-inducing signaling-complex (DISC). This complex recruits caspases 8 and 10 via 
the interaction of their death-effector proteins domains (DED) with the DED of the adaptor 
molecule FADD. Caspases are the main effectors of the extrinsic apoptotic pathway. They are 
a family of over a dozen cystein proteases that cleave at aspartic acid (Asp) residues. 
Caspases are expressed as latent zymogens and require cleavage (through each other mostly) 
for activation. The sequential activation of one caspase by another creates an expanding 
cascade of proteolytic activity culminating in the activation of Caspase-3. Caspase-3 is the 
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end-effector of the apoptotic process, which results in proteolytic cleavage of cellular 
substrates, digestion of structural proteins in the cytoplasm and degradation of chromosomal 
DNA. This is visible microscopically in the formation of apoptotic bodies, which represent a 
specific morphological change of the cell in response to apoptosis. Their formation leads to 
subsequential phagocytosis of the cell. 
1.5.2 The intrinsic (mitochondrial) pathway 
Stress conditions, such as starvation, or damage to a cell's DNA from toxicity or exposure to 
ionizing radiation such as ultraviolet or X-rays, induce an apoptotic process from within the 
cell via the mitochondrial pathway31 (Figure 1.4, B). This causes a change in the permeability 
of the mitochondrial membrane by triggering specific Bcl-2 family-regulated mechanisms, 
resulting in the release of cytochrome c from the mitochondria. Each of the Bcl-2 family 
members is either pro- (Bad, BAK, Bax, tBID, BIM, etc.) or anti-apoptotic (Al, Bcl-2, Bcl-w, 
Bcl-xL, etc.), and it is the balance between these factors that will determine cytochrome c 
release and therefore apoptosis.32-34 In a healthy cell, the outer membranes of its mitochondria 
express the anti-apoptotic protein Bcl-2 on their surface. Bcl-2 is bound to a molecule of the 
protein APAF-1 ("apoptotic protease activating factor-1 "). Internai damage to the cell causes 
Bcl-2 to release APAF-1 and a related protein, Bax, to penetrate mitochondrial membranes, 
causing cytochrome c to leak out. The released cytochrome c and Apaf-1 recruit procaspase-9 
via its capase recruitment domain (CARD), and the resulting complex of cytochrome c, Apaf-
1, caspase 9 and dA TP is called the apoptosome. 35 Apoptosomes aggregate in the cytosol and 
lead to caspase-3 activation. 
Caspase-3 is the common end-effector of both pathways. Under normal conditions, proteins 
of the inhibitor of apoptosis-family (IAP)36 directly bind and inhibit capase-3, -6, -7, and -9. 
However, when a cell receives an apoptotic stimulus, the inhibitory IAP activity is itself 
inhibited by the release of SMAC (Second Mitochondria-derived Activator of Caspases, its 
mouse homolog being DIABLO). When SMAC binds to IAPs, it enables the apoptotic 
process to continue and conclude in cell death. 15• 37 
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FIGURE 1.4 The two major apoptotic pathways in mammalian cells 
A. The death -receptor pathway (extrinsic pathway) 
Binding of the ligand (FasL) to the death-receptor Fas, induces receptor clustering on the cell membrane and 
formation of a death-inducing signaling complex (DISC). This complex recruits multiple procaspase-8 
molecules via the adaptor molecule F ADD (Fas-associated death domain protein), leading to a caspase-
caspase activation cascade beginning with Caspase-8 and ending with Caspase-3 activation and apoptosis. 
Caspase-8 activation can be blocked by FLIP. 
B. The mitochondrial pathway (intrinsic pathway) 
This pathway is used in response to various apoptotic stimuli, such as DNA damage by radiation or reactive 
oxygen species. The lethalness of the stimuli is evaluated on the mitochondrial surface, where there is a 
competition between pro-apoptotic members of the Bcl-2 family, like Bax, and anti-apoptotic members, like 
Bcl-2 and Bcl-xL. If the death agonists prevail, cytochrome c is released from the mitochondria and 
associates with APAF-1 and Caspase 9 to form an apoptosome which enables Caspase-3 activation and 
subsequent apoptosis. 
Both the pathways converge at the level of Caspase-3 activation which can be antagonized by IAP proteins, 
which in turn are inhibited by the SMAC/DIABLO protein released from mitochondria. 
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1.5.3 T cells and apoptosis 
In T cells, the death receptor pathway is also often termed AICD (activation-induced cell 
death), as it results through repeated activation of the TcR. The importance of apoptosis in the 
human immune system is illustrated by the autoimmune lymphoproliferative syndrome 
(ALPS). ALPS is defined by functional analysis of lymphocyte sensitivity to Fas-induced 
apoptosis in vitro. The T cells of these patients are completely or partially resistant to AICD 
according to the severity of the genetic mutations of Fas, FasL or caspase-8.38'39 Four criteria 
characterize the ALPS condition: a lymphoproliferative syndrome (splenomegaly and/or 
lymphadenopathies ), autoimmune manifestations, hypergammaglobulinemia and detection of 
CD4-CD8- T cells (double negative or DN cells) in the blood. Apart from rare exceptions, 
ALPS patients usually present at least three of these criteria.40 
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2 OBJECTIVE and APPROACH 
As discussed in the introduction, a functional division of memory T cells into central and 
effector memory cells would logically imply a differential susceptibility of the distinct 
memory T cell subsets to cell death or to survival signals (Figure 2). However, the 
mechanisms underlying the promotion of cell survival or cell death in memory cells are 
poorly understood, and various genes have been attributed pivotal roles in this regulation. 
FIGURE 2 
G G 
Working Hypothesis: Differential susceptibility of memory subsets to survival 
and death signais 
In a linear differentiation model, the expansion potential and proliferative capacities of central memory T cells 
(T cM) would have to be greater than those of effector memory (T EM) and terminally differentiated effector 
memory T cells (T TEM), in order to enable them to act as a reservoir for the more differentiated subsets. The 
effector memory populations, on the other hand, would show higher susceptibility to apoptosis than the central 
memory subset. 
The aim of this study is to elucidate as to whether, in the case of memory T cell subsets, a 
difference of susceptibility to cell survival can be mirrored by a differential gene expression 
pattern in the individual subsets. For this purpose, a panel of 12 genes involved in apoptosis 
and survival was selected and studied in each memory subset separately. The various 
individual genes are discussed in the following chapter. 
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The approach has required a method allowing analysis of gene expression in a restricted 
number of cells and simultaneous comparison of the expression levels. Accordingly, the study 
can be divided into three steps: 
1. Design of a real-time RT-PCR assay by which to analyze gene expression in a 
restricted number ofhuman T lymphocytes. 
2. Validation of a suitable endogenous reference gene for relative quantification. 
3. Semi-quantitative analysis of the expression pattern of gene panel memory 
subpopulations of CD8+ and CD4+ peripheral human T cells and comparison to 
naïve CD8+ and CD4+ T cells, respectively. 
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3 GENEPANEL 
3.1 SURVIVAL GENES 
The generation and survival of memory T cell populations are crucial for prolonged protective 
immunity following infection. Memory lymphocytes are generated in the presence of antigen; 
their maintenance and persistence, however, is independent of TCR-mediated signals, as 
shown by studies demonstrating memory T cell survival in MHC-deficient mice.41 '42 
Cytokine-induced homeostatic proliferation has been proposed as a mechanism to replenish 
the numbers of memory T cells in the absence of specific antigen, and various cytokines have 
been implicated in the long-term survival of memory T cells.43-45 
3.1.1 IL-15 
In humans, interleukin 15 (IL-15) was originally discovered as a cytokine produced by a 
human adult T cell leukemia cell line (HuT-102). It was shown to stimulate T cell 
proliferation and was designated IL-T.46 IL-15 is a cytokine that shares many biological 
properties with IL-2. Apart from stimulating T cell proliferation,47 it has been found to 
provide survival signals to support the growth of mature lymphocytes,44 particularly activated 
peripheral blood T lymphocytes.47-49 In addition, IL-15 has also been shown to be a 
chemoattractant for human blood T lymphocytes50 and to be able to induce the generation of 
cytolytic effector cells. 
Many types of cells secrete IL-15, but apparently this cytokine is not produced by T cells 
themselves; 51 IL-15 mRNAs have been detected in several human tissues and cell types, 
including heart, lung, liver, placenta, skeletal muscle, epithelial and fibroblast cell lines, but 
have not been detectable in activated peripheral blood T cells.47 
3.1.1.1 IL-15-Receptor (IL-15Ra) 
IL-15 signals through a trimeric receptor complex. IL-15-Receptor (IL-15R) consists of (1) 
the common y-chain which is shared by IL-2, IL-4, IL-7, IL-9 and IL-21 for signal 
transduction, (2) the ~-chain which is shared by IL-2 and also called IL-2R~, and (3) most 
importantly, a unique high affinity a-chain (IL-15Ra). These high-affinity cell surface 
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receptors for IL-15 have been detected on a variety of T cells and B cells, as well as non-
lymphoid cells.52 
3.1.1.2 IL-15 andmemory Tcells 
IL-15 does not seem necessary to mount primary CD8+ T cell responses. Thus, studies in IL-
15-/- and IL-15Ra_1_ mice have shown that IL-15 is not required to efficiently clear the 
pathogen and generate a pool of antigen-specific CD8+ T cells. However, there is strong 
evidence showing that IL-15 can promote proliferation and long-term survival of memory 
phenotype CD8+ T cells in an antigen-independent fashion. 20•27 These cells express the a-
chain of the IL-15-Receptor and the shared IL-2-R ~- and y-chains, individually or together, 
to form various functional receptors with different affinities and signaling capabilities. The 
interaction of IL-15 with its receptors was shown to lead to a potent and selective proliferation 
of CD8+ memory T cells.43 •44 '53 
3.1.2 IL- 7 
Interleukin 7 (IL-7)54 is essentially a tissue-derived cytokine and is produced by several 
stromal tissues, including epithelial cells in thymus and bone marrow. 55 Additional sites of IL-
7 production include intestinal epithelium, keratinocytes, fetal liver, adult liver, dendritic cells 
and follicular dendritic cells.56-60 Interestingly, however, IL-7 mRNA has not been detected in 
normal lymphocytes. IL-7 has been shown to bind to extracellular matrix-associated 
glycoproteins, such as glycosaminoglycan, heparan sulfate and fibronectin. It is thought that 
this plays an important role in the regulation of IL-7-induced signaling within the cellular 
microenvironment. 61 •62 All in all, several studies have shown the importance of IL-7 in the 
regulation of T cell survival. 43 ' 63-70 
3.1.2.1 Signal transduction 
The IL-7-Receptor consists of two polypeptides: (1) a highly specific a-chain (IL-7Ra or 
CD127), and (2) the common y-chain, which is the same as for the IL-15-Receptor. Binding 
of IL-7 to the IL-7Ra-chain leads to dimerization of the a- and y-chains and subsequent signal 
transduction. The a-chain is activated through phosphorylization by JAK-3 and the tyrosine 
kinase of the y-chain. Once phosphorylated, the a-chain serves as a site for recruiting other 
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signaling molecules to the complex, to be phosphorylated and activated it tum. The most 
important targets of this signal transduction are STAT5, the src family kinases (lck and fyn), 
PB kinase, Pyk2 and Bcl2 proteins. The activation of these signaling molecules promotes 
different pathways in T cells. Bcl-2 and Pyk-2 have an enhancing effect on cell survival. PB 
kinase, src family kinases (lclc and fyn) and STAT5, on the other band, contribute to cellular 
proliferation. The transcription factor STAT5 migrates into the nucleus and leads to the 
activation of multiple downstream genes essential to proliferation and development in B and 
T cells (Figure 3.1). 71 -73 
JAK 1 
I 
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... 
1 PYK2 J / 
(eét-2) <êr_ ? 
CELL SURVIVAL 
FIGURE 3.1 Overview of the IL-7 signaling pathway 
See text for explanation. 
(Note: Figure adaptedfiwn Croston G. 74). 
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3.1.2.2 IL-7 in developing and mature naïve T cells 
IL-7 is best known for its effects on developing B-cell and T-cell populations, e.g. its crncial 
role in thymopoiesis,75-77 but it also potently modulates mature, naïve T-cell function.78 One 
of the major effects of IL-7 on naïve T cells is the inhibition of programmed cell death. In this 
manner, IL-7 acts as a trophic factor for mature T cells, similar to the effects observed on 
developing B and T lymphocytes - partly through the upregulation of Bcl-2 family 
molecules63-65 and potentially through the upregulation of the T-cell survival factor, lung 
Kruppel-like factor. 67 Not surprisingly then, IL-7 enhances T-cell survival in long-te1m cell 
cultures and, in some studies, IL-7 was shown to be superior to IL-2 in this regard.69 The 
survival of T-cells in general is increased by IL-7 inhibiting apoptosis. Furthermore, IL-7 
plays an important role in the case of naïve T cells. Thus, in animals, naïve cells seem to be 
kept alive in absence of antigen by continuous interaction of self-peptides bound to MHC and 
exposure to IL-7 .75'76 In particular, IL-7 has been found to be present in secondary lymphoid 
tissue, a location that is part of naïve CD4+ T-cell circulation. When naïve CD4+ T-cells are 
removed from their micro-environment, they quickly die. CD4+ T cells bear the IL-7R on 
their cell surface and have been shown to be maintained in vitro for up to 15 days in the 
presence ofIL-7, suggesting that it is a survival factor for these cells.78 
IL-7 has also been shown to drive the activation and proliferation of resting CD4+ and CDS+ 
T-cells along a pathway that is independent of IL-2.79 It also directly enhances cytolytic 
function of mature CDS+ T-cells. Moreover, recent in vitro studies in mice indicate that IL-7 
restores immune competence by a thymus-independent pathway.65 It increases peripheral 
expansion ofT lymphocytes by inhibiting apoptosis and enhancing the survival of T cells, as 
well as increasing the antigenic capacity of APCs. Thus, in patients with AIDS, the plasmatic 
level of IL-7 is higher than in healthy donors and has been shown to be inversely correlated 
with the level of CD4+ T cells. This possibly reflects an attempt to restore nmmal T cell levels, 
since these high levels ofIL-7 decrease under ART when T cell counts increase.80 
3.1.2.3 IL-7 and memory T cells 
The combination of enhanced costimulation and programmed cell death inhibition by IL-7 is 
probably responsible for the role of IL-7 in facilitating memory T-cell differentiation in vivo. 
Unlike IL-15, which is absolutely required for the developmentofmemory T-cell populations, 
the absence of physiologie levels of IL-7 leads to a significant reduction in the number of 
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memory T cells generated following a primary antigenic stimulus in vivo.43 '68 It is not known 
as to whether supra-physiologie doses administered at the time of primary antigen exposure 
can actually increase the number of long-term memory cells generated in vivo, but such 
studies will be important in determining the potential role of IL-7 as a vaccine adjuvant. By 
similar mechanisms as in the case of naïve T cells, IL-7 might promote cell survival of 
memory cells as well. For example, increased survival was found to be concomitant with the 
upregulation of anti-apoptotic protein Bcl-2 expression and memory cell markers in total 
CD4+ cells. The requirement of IL-7 for CD4+ memory T-cell generation and persistence has 
been confirmed in recipient mice which were rendered deficient in IL-7 through a blocking 
IL-7 antibody. 81 '82 
3.1.3 BAFF, APRIL and their receptors BAFF-R, TACI and BCMA 
BAFF (B cell-activating factor of the TNF-family; also termed B-lymphocyte stimulator, 
BLyS; TALL-1, THANK, zTNF4) and APRIL (A PRoliferation-Inducing Ligand, also 
termed TRDL-1, TALL-2) are recently discovered members of a new subfamily of TNF-like 
ligands that are expressed in haematopoietic cells (Figure 3.2). 83-90 They have two common 
receptors: Transmembrane activator and calcium modulator cyclophilin ligand interactor 
(TAC!) and B-cell maturation antigen (BCMA). The third receptor, BAFF-R (or BR3) is a 
specific receptor to BAFF only. The existence of a specific receptor to APRIL is suspected, 
but has yet to be proven. Until now, these proteins have been extensively, but almost 
exclusively, studied in B cells. They have been shown to provide essential survival signals to 
activated B cells by inducing upregulation of antiapoptotic proteins such as Bcl-2, by down-
regulation of proapoptotic proteins such as Bim, and possibly through blockade of the Fas-
dependent apoptosis pathway.92 
3.1.3.1 BAFF 
BAFF is a homotrimeric protein. It is either expressed as a type II transmembrane protein on 
the cell surface, or is released in a soluble form after cleavage by furin-type proteases. It is 
produced by macrophages, monocytes and dendritic cells.93 '94 BAFF is not expressed by B 
cells and its expression on T cells remains controversial. Indeed, very little is known about 
BAFF in T cells. However, one group has demonstrated efficient TcR stimulation through 
BAFF and anti-CD3 in the absence of anti-CD28. They concluded that BAFF might thus have 
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a co-stimulatory role in T cells.95•96 In some cases, BAFF may act in an autocrine manner.93 '94 
It has also been reported that BAFF and APRIL form biologically active heterotrimers.97 
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FIGURE 3.2 Overview of the TNF-like-ligands BAFF and APRIL and their receptors. 
The TNF-like ligand BAFF binds specifically to it receptor BAFF-R, thereby inducing Bcl-2 and peripheral B-
cell survival. BAFF also interacts with the receptor TACI and, to a lesser extent, with BCMA, both of which 
bind APRIL as well. APRIL-R may be a specific, hypothetical receptor to APRIL. 
(Note: Figure adaptedfiwn Vaux, D.L. 91) 
3.1.3.2 .r4J>J?.JJ_, 
APRIL shares a very similar amino-acid sequence with BAFF, making it probable that the 
two ligands share biological activities. APRIL transcript levels are reported to be low in 
normal tissues, among which the highest levels are found in peripheral blood leucocytes.98 In 
contrast, much higher mRNA levels have been detected in tumor cell lines and in a variety of 
. . 98-101 pnmary tumor tissues. 
It has been shown that APRIL promotes proliferation in human T cell lines, such as Jurkat 
cells and also in NIH-3T3 cell lines.98 In normal T cells, several reports propose a role for 
APRIL as a T-cell stimulator. For instance, anti-APRIL antibodies have been shown to 
prevent T-cell stimulation in vitro. 102-104 T cells derived from APRIL transgenic mice show 
significantly increased proliferation after in vitro activation; this was especially evident after 
stimulation with anti-CD3anti-CD28. 105 The proliferative effect induced by APRIL could be 
mediated by TACI, whose cell surface expression is upregulated following T-cell 
activation. 106 
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Apart from having an effect on proliferation, transgenic APRIL-expressing T cells have a 
highly significant increase in in vitro survival under conditions in which cells are deprived of 
survival factors and receive suboptimal or no activation signais. This coincides with increased 
Bcl-2 expression in the same cells, which would explain the protection against growth factor 
deprivation-induced apoptosis. 107 APRIL also seems to induce resistance to apoptosis by 
upregulating X-linked inhibitor of apoptosis (XIAP), a member of the inhibitor of apoptosis 
(IAP) family 101 (Figure1.4, General Introduction). 
3.1.3.3 BCMA, TACI and BAFF-R 
The signal transduction pathways used by BCMA and TACI have not been fully 
characterized. BCMA binds TNF receptor-associated factors TRAF 1, 2 and 3, which appear 
to mediate NF-KB, p38, mitogen-activating protein kinase (MAPK) and c-Jun NH2-terminal 
kinase (JNK) pathway activation. T ACI engagement, on the other hand, results in activation 
ofNF-KB, AP-1 and NF-AT via TRAF 2, 5 and 6. 106 
3.2 GENES OF THE APOPTOSIS PATHW AY 
The apoptosis pathways contain many control points regulated by either anti- or proapoptotic 
proteins. The mitochondrial pathway is closely regulated by proteins belonging to the Bcl-2 
protein family. They have been classified into three functional groups. Members of the first 
group, such as Bcl-2 and Bcl-xL, possess anti-apoptotic activity and confer protection from 
cell death. In contrast, groups II and III consist mainly of pro-apoptotic proteins, such as Bax, 
Bak and Bim and promote cell death. The ratio of death antagonists to agonists determines 
whether a cell will respond to an apoptotic signal. In part, this ratio is determined by 
competitive dimerization between selected antagonists and agonist molecules which form 
heterodimers. In this manner, Bcl-2 protein family members can intimately regulate 
cytochrome c release from the mitochondria and either induce or inhibit apoptosis32' 108-110 
(Figure 1.4, General Introduction). 
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3.2.1 Anti-apoptotic genes: Bcl-2, Bcl-xL and FLIP 
3.2.1.1 Bcl-2 
The Bcl-2 proto-oncogene is a cytoplasmic protein that contains two evolutionarily conserved 
domains, termed BHl and BH2. It is the founding member of the large Bcl-2 protein family 
and is one of the most well characterized survival proteins in the immune system. It is 
essential for the survival of both B and T cells. 108 Thus, it has been shown that overexpression 
of Bcl-2 in lymphocytes leads to an increased resistance to irradiation-induced death in 
vitro. 111 Bcl-2 prevents apoptosis by inhibiting the release of mitochondrie proteins into the 
cytosol. 112 It can act either directly on its own as a suppressor of programmed cell death, or 
indirectly by interacting with the pro-apoptotic protein Bax. By forming heterodimers with its 
homologue, Bcl-2 binds and inhibits Bax, thereby indirectly promoting cell survival. 
3.2.1.2 Bcl-xL 
Similarly to Bcl-2, Bcl-xL also protects cells from multiple apoptotic stimuli. 113- 114 Apart 
from its role in thymie development, 115- 116 where it protects CD4+ CD8+ DP cells from 
apoptosis, it has been documented to increase the half-life of peripheral mature T cells. 117 
3.2.1.3 fl'LIJ> 
FLIP belongs to a navel family of apoptosis inhibitors, 118 also termed FLICE/caspase-8 
inhibitory proteins. v-FLIP was first discovered as an anti-death receptor-induced apoptosis 
factor in y-herpesvirus. The cellular homolog, c-FLIP (also CASH, Casper, CLARP, FLAME, 
I-FLICE, MRIT or usurpin) has at least two splice variants, the long 55-k:Da form (c-FLIPL) 
and the short 26-k:Da form (c-FLIPs). FLIPL is expressed in many tissues, most abundantly in 
heart, skeletal muscle, lymphoid tissue and kidney; FLIPs is additionally detectable in 
lymphatic tissue. 
FLIP inhibits apoptosis by interacting with caspase-8. Caspase-8 is the key initiator caspase 
downstream of the extrinsic apoptosis pathway induced by Fas and other death receptors 
(fl'igurel.4, General Introduction) and interacts with FADD through homologous death 
effector domains. Aggregation and proximity result in the activation of caspase-8 by 
processing the caspase domain into two active subunits. FLIP is structurally similar to 
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caspase-8 and also possesses death effector domains (DED), as well as a caspase-like domain. 
However, it lacks caspase enzymatic activity. Thanks toits structural homology with caspase-
8, FLIP competes with capase-8 at the level of the DISC ( death-inducing signaling complex). 
Its DED-terminal enables FLIP to internet with the Fas-associated adaptor molecule F ADD 
and be recruited to the Fas/FasL complex in the place of caspase-8. By these means, FLIP 
impedes the progression of apoptotic signals and blocks activation-induced cell death (AICD). 
AICD is an important mechanism for T cell homeostasis, because it intervenes after the 
expansion phase triggered by antigen-recognition and induces a phase of increased cell-death 
which counterbalances increased T cell numbers. Additionally, FLIP enables the recruitment 
of multiple signaling molecules to the DISC, leading to the activation on NF-KB and ERK 
pathways, thus also accounting for a pro-survival effect. 
Besicles its anti-apoptotic function, FLIP is suspected to play an important role in embryonic 
development. FLIP knock-out mice do not survive past day 11 of embryogenesis and show 
signs of cardiac failure associated with impaired heart development. 119 
3.2.2 Pro-apoptotic genes: Bax and Bad 
3.2.2.1 Bax 
Bax is a protein with a molecular weight of 21 kDa and plays an important role in the 
regulation of cell death in a number of eukaryotic cells. The over-expression of Bax has been 
shown to accelerate cell death. The ratio of Bax to other Bcl-2 family members and its 
subcellular distribution are thought to help regulate the process of programmed cell death. It 
can be directly inhibited by Bcl-2 with which it forms heterodimers. 108•120 
3.2.2.2 Bad 
Bad is a promoter of apoptosis that has been shown to dimerize with the anti-apoptotic 
proteins Bcl-2 and Bcl-xL. It is supposed to bind these anti-apoptotic members of the Bcl-2 
family through its BH3-domain. In this manner, Bad inhibits the survival promoting functions 
of these proteins and promotes cell death.32•108 
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3.2.2.3 Fas-Ligand 
Fas-ligand (FasL) is the ligand to the death-receptor Fas (CD95). FasL-Fas interaction is the 
first step in the extrinsic pathway (Figure 1.4, General Introduction) and induces the 
clustering of several death-receptors on the cell membrane and recruitment of the Fas-
associated death domain adapter protein (FADD). FADD is a bipartite molecule with a death-
effector-domain (DED) N-terminal and a death-domain (DD) C-terminal. It binds to Fas by 
means of homophilic DD-DD interactions and recruits caspase-8 by the means of DED-DED 
interactions. This results in the formation of a death-inducing signaling complex (DISC), 
enabling neighboring caspase-8 molecules within this newly formed complex to 
proteolytically activate each other. Subsequently, apoptosis is initiated by cleavage and 
activation of the downstream effector caspases, such as caspase-7, -6 and -3. 121 
Stimulation of the TcR in conjunction with appropriate co-stimulation, not only results in the 
activation and differentiation of T cells, but also renders them susceptible to Fas-mediated 
apoptosis. In fact, T-cell activation leads to the increased expression of Fas and FasL, 122 
permitting the activated T cells to eliminate neighboring Fas-positive cells. By this 
mechanism, the expression of Fas and FasL is crucial to T cell homeostasis. Indeed, mice 
deficient in Fas or FasL show massive lymphoadenopathy and disruption of lymphocyte 
homeostasis due to a lack of programmed cell death. Interestingly, however, CD4+ memory T 
cells are more resistant to Fas-induced death in vitro. 123,124 
3.3 ANTI-PROLIFERATIVE GENE: TOB 
Proliferating cells undergo mitosis, e.g. a parent cell replicates its DNA to form genetically 
identical daughter cells. Mitogenic signaling allows cells to progress from a non-dividing, 
quiescent state (Go) through the G1/S phase of the cell cycle. Once they have crossed this 
restriction point and have entered the S phase, which corresponds to the DNA replication 
phase, cells are programmed to <livide and undergo mitosis. Many genes control cell cycle 
progression, and abnormalities in this control contribute to the development of cancer. Thus, 
cellular homeostasis is tightly regulated by systematic activation and/or inactivation of 
proliferative and antiproliferative genes. 
Tob is a member of the BTG anti-proliferative protein family, which also includes B cell 
translocation gene (BTG 1 and BTG2), abundant in neuroepithelial area (ANA) and Tob2. 
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These proteins all share structural and functional characteristics. Members of this family have 
been isolated from libraries of various cell types, including malignant cells, NIH3T3 and 
PC12 cells. In these cell types, BTG-family proteins are rapidly induced in response to growth 
factors and tumor promoters. 125 On the functional level, however, these gene products, when 
overexpressed, suppress cell growth by inhibiting cell cycle progression. 126 Another important 
common feature is that the proteins of this family are associated with transcription factors 
such as Cafl, Hoxb9 and Smad. 
Mice lacking the Tob gene frequently develop tumors and show an osteopetrotic phenotype 
that is caused by the facilitated growth and differentiation of osteoblasts. 127 All this strongly 
suggests the importance of Tob in cell growth regulation. The antiproliferative action of Tob 
has been analyzed by exogenously expressing Tob in NIH3T3 cells. In this case, Tob 
expression has been shown to inhibit cell cycle progression in the G1 phase by suppressing 
cyclin Dl expression. Alternatively, Tob can be inactivated by growth-factor-induced 
phosphorylation, canceling cyclin Dl suppression. This phosphorylation of Tob is catalyzed 
by Erkl/2, thus linking MAPK activity to cyclin Dl expression. 128-129 
3.3.1 Tob and T cells 
Peripheral tolerance mechanisms play an indispensable role in the maintenance of natural 
self-tolerance: autoimmune responses are averted and inflammatory reactions are controlled. 
One of the mechanisms of peripheral tolerance is induction of anergy. One way of achieving 
this state is through suboptimal TCR-triggering. The state of anergy has been shown to 
correspond to a blockade of the cell cycle in the G1 phase. 
In the effort to identify genes preferentially linked to an anergie state, Tob was recently 
shown to be selectively expressed in anergie clones. When further examining Tob expression 
in T cells, Tob was found to be constitutively expressed in quiescent human peripheral blood 
CD4+ T lymphocytes. Upon stimulation with anti-CD3 and anti-CD28 antibodies, as well as 
after IL-2 stimulation, however, Tob mRNA was found to be downregulated to almost 
undetectable amounts. By expressing human Tob as a fusion protein, Tzachanis D et al. 126 
could induce inhibition of anti-CD3-induced T cell proliferation. This inhibition was directly 
related to the levels of Tob expression. In the same manner, the fusion protein also inhibited 
the production of IL-2 and other cytokines. 
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When examining the role of Tob on a molecular level, Tob was shown to allow cells to enter 
into the G1 phase of the cell cycle (as determined by Cdk4 expression). The lack of cyclin A 
expression, however, demonstrated that Tob concomitantly inhibited progression into the S 
phase. Thus, it can be concluded that Tob actively blocks the cell cycle in the G1 phase and 
before the G1 --+S restriction point. Immunoprecipitation assays showed that Tob associates 
preferentially with Smad2 and Smad4. Smads are known to function as negative regulators of 
T cell activation. They mediate signals induced by TGF-P superfamily members, resulting in 
inhibition of anti-CD3- and anti-CD28-mediated stimulation of T cells. Tob and Smad 
interaction may enhance Smad binding to the negative-regulatory element of the IL-2 
promotor, thus blocking IL-2 transcription (Figure 3.3). Hence, Tob may actively maintain 
the resting state of T cells by preventing cell cycle progression. If this is the case, the 
repression of Tob would be mandatory for T cell activation. 
FIGURE 3.3 Hypothetical role of Tob in maintenance of T cell quiescence and possible 
connection of Tob to the TGF-13 signaling pathway. 
Tob has been shown to be selectively expressed in quiescent T cells and to internet preferentially with Smad2 
and Smad4. The Smad proteins bind the IL-2 promoter and may therefore also recruit Tob to the promoter, 
enhancing the inhibition of IL-2 transcription. Thus, Tob may actively maintain the quiescent state of T 
lymphocytes. Anti-CD3 and anti-CD28 stimulation, however, could tum off the expression Tob. This would 
relieve the repression of IL-2 transcription and promote T cell activation. It remains to be determined whether 
lung-Krüppel-like-factor (LKLF) induces the expression ofTob. 
(Note: Figure adaptedjiwn Tzachanis D et al. 126). 
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4 MATERIALS AND METHODS 
4.1 SUBJECTS 
Buffy coats from healthy blood donors were obtained from the Lausanne Blood Transfusion 
Centre. Bach healthy donor was identified by the prefix LHD, followed by a number. Samples 
were screened by flow cytometry for the percentages of CD4+ and CD8+ T cells prior to use. 
Subjects with adequate cell numbers and subpopulation percentages for sorting were selected. 
Thus, four different subjects (LHD 216, 234, 283 and 288) were used for the analysis of gene 
expression in CD8+ cells, and three subjects (LHD 216, 283 and 288) were chosen for analysis 
of CD4+T cells. 
4.2 MATERIALS AND SOLUTIONS USED 
Ficoll-PAQUE Plus 
PBS: 
EDTA: 
FBS: 
Phosphate-buffered saline lx 
Ethylenediaminetetraacetic acid 
Fetal Bovine Serum 
Cell Culture Medium: 
-RPMI 1640 Glutamax-1 medium 
-Penicillin 0.1 % 
DMSO: Dimethyl-sulphoxide 
(Amersham, Pharmacia Biotech AB) 
(CHUV Pharmacy) 
(SIGMA) 
(GIBCO BRL, Life Technologies) 
(GIBCO BRL, Life Technologies) 
(GIBCO) 
(SIGMA) 
Freezing solution: 52.5% Cell culture medium, 40% FBS, 7.5% DMSO 
P2: PBS lx, 2% FBS 
RlO: Cell culture medium lx, 10% FBS 
R20: Cell culture medium lx, 20% FBS 
4.3 ISOLATION, PRESERVATION AND THAWING OF CELLS 
Peripheral blood mononuclear cells (PBMC) from healthy donors were separated by density 
gradient centrifugation. For this, the buffy coats were washed with 100 mL of PBS containing 
EDTA at a 2 Mm concentration. 25 ml of the solution was gently added over 15 ml of Ficoll-
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Paque Plus and centrifuged for 20 min at 836 g without the brake, so as not to disturb the 
layering. Differential sedimentation during centrifugation resulted in the formation of layers 
containing different blood cell types. Because of their low density, lymphocytes gather at the 
interface between the plasma (lowest density) and the Ficoll-Paque (highest density) along 
with other slowly sedimenting cells, such as platelets and monocytes. The white disk 
corresponding to the PBMC was recuperated with a Pasteur pipette and cells were washed 2 
times with PBS-FBS 2% to remove any platelets. Cells were counted and re-suspended in 
freezing solution, containing medium, FBS and DMSO. Aliquots of approximately 10 million 
cells per vial were preserved at -80 °C in liquid nitrogen. Bach buffy coat delivered between 
120-250 million cells. 
Before use, the cryo-preserved PBMC were thawed by putting them in a water bath at 37.5°C 
and adding R20 solution drop-by-drop, while swirling the cells continuously. Cells were spun 
down at 677 g and the supernatant was discarded. Subsequently, the cells were washed with 
RI 0 and P2 solutions. The recuperation rates after thawing were between 60-100%. 
4.4 STAINING AND SORTING OF MEMORY T CELL SUBPOPULATIONS 
4.4.1 Staining 
PBMC were thawed, washed and re-suspended in PBS-FBS 2% before staining. Cells were 
stained with the required fluorochrome-labelled primary monoclonal antibodies (Table 1). 
TABLE 1 
CD4-PE 10 
CDS-PE 10 
CD45RA-CyChrome 15 
CD45RO-FITC 15 
CD4-FITC 15 
CDS-FITC 12 
Pure CCR7 0.5 
Goat anti-rat IgG-PE 5 
Antibodies used in this study for the FACS-Vantage 
All antibodies were rat anti-human (ifnot indicated otherwise) and purchased from BD. 
(Q: quantity in ~Ll per million cells) 
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Each layer was incubated for 30 minutes at 4°C in the darlc, washed and then re-suspended in 
P2 solution at a concentration of approximately 3 million cells per ml after staining and sorted 
immediately. The anti-CCR7 staining was indirect and revealed with PE-conjugated goat anti-
rat IgG. 
4.4.2 Sorting and FACS analysis 
Cells were sorted on a FACS-Vantage flow cytometer (Becton Dickinson Immunocytometer 
Systems) using FITC, PE and CyChrome as fluorescent colors. Screening of donors was 
performed by 6-parameter flow cytometric analysis on a F ACS-Calibur flow cytometer 
(Becton Dickinson Immunocytometer Systems), using FITC, PE, CyChrome or CyChrome 
Cy5.5 and APC as fluorescent parameters (Figure 4.1). BD CellQuest Pro Software was used 
for data acquisition and analysis. 
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FIGURE 4.1 Sorting of human T cell populations by flow-cytometry. 
A: The encircled population of PBMC corresponds to lymphocytes 
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27.3 45.3 
19.6 7.S 
Band C: CD4+ and CDS+ T cells are separated into 4 populations consisting of: (1) Naïve, CD45RA+ CCR7+ T 
cells (upper right quadrant); (2) Central memory, CD45RA- CCR7+ T cells (lower right quadrant); (3) Effector 
memory CD45RA- CCRT T cells (lower left quadrant) and (4) Terminal effector memory CD45RA+ CCRT 
T cells (upper left quadrant). The percentages of each population are noted in the grid. 
4.5 REVERSE TRANSCRIPTION AND REAL-TIME PCR 
Reverse transcription-polymerase chain reaction (RT-PCR) is an m vitro method for 
enzymatically amplifying defined sequences of RNA. It is one of the most sensitive and 
flexible methods to quantify transcription levels of genes and capable of detecting mRNA 
from as little as a single cell. It can be used to compare levels of mRNAs in different sample 
populations and to characterize patterns of mRNA expression. Total RNA is used as a 
template for a reverse transcription reaction using an enzyme (reverse transcriptase, RT) that 
transcribes RNA into cDNA (complementary DNA). The cDNA is subsequently used in a 
polymerase chain reaction (PCR), together with primers which will specifically hybridize 
with the sequence of interest and amplify it. The amplified sequence can then be detected by 
either using a non-quantitative method ( e.g. gel electrophoresis) or in a quantitative analysis. 
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4.5.1 RNA extraction 
RNA extraction was performed using the MiniRNEasy Kit (QIAGEN) according to the 
manufacturer's instructions. To be sure to have the same number of cells per extraction, 
15'000 cells of each T cell subpopulation were sorted separately by the F ACS Vantage into 
Eppendorffs containing 200 µl of FBS and 300 µl of cell culture medium. Cells were spun 
down, the supematant was discarded and the remaining cell-pellet was re-suspended in PBS-
FCS 2% previous to RNA extraction. Extracted total RNA was eluted in 12 µl of nuclease-
free water and stored at minus 56°C (-56°C). 
4.5.2 Reverse Transcription (RT Reaction) 
First strand complementary DNA was synthesized in a final volume of 50 µl using the 
TaqMan® RT-kit (Applied Biosystems, TaqMan Reverse Transcription Reagents -PIN N808-
0234). Cryo-preserved RNA was heated for 1 minute at 65°C, put on ice and immediately 
added to the RT-mixture. The RT-mixture contained RT-Buffer, MgCh, deoxyribonucleoside 
triphosphate mixture (dNTPs), Random Hexamers, Ribonuclease Inhibitor, MultiScribe 
Reverse Transcriptase and nuclease-free water and was aliquoted under a PCR hood previous 
to adding RNA. Samples were incubated at 25°C for 10 minutes, elongation was performed at 
48°C for 30 minutes and enzyme was deactivated at 95°C for 5 minutes. Each sample 
contained total RNA from 15'000 sorted cells. A stock RNA from total CD4+ T cells, with 
subsequent C-alpha PCR amplification, was used as a control for the RT step. 
4.5.3 Principles of Real-Time PCR 
A basic PCR run can be split into three phases. In the beginning, assuming 100% reaction 
efficiency, there is exact doubling of the product at every cycle (exponential phase). In the 
linear phase, the reaction components are consumed and the reaction slows down. In the 
plateau phase, the reaction has stopped; no more products are being made and, if left long 
enough, the PCR products will degrade. 130 Traditional PCR measures the product at the end-
point (plateau phase) by gel detection. However, quantification at this point is inaccurate 
because amplification is only exponential in the initial phase, when all the reagents are fresh 
and available (Figure 4.2). 
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For accurate quantitation, it is necessary to detect the PCR product in the initial phase of the 
reaction. This was achieved by incorporating fluorescence techniques into the PCR reaction, 
such as with the TaqMan Probe (Figure 4.3). The increase in fluorescent signal is directly 
proportional to the number of amplicons generated. Thus, it is possible to monitor the real-
time progress of the the PCR and collect data in the exponential growth phase. The 
fluorescent signal, proportional to the amplification, is captured by a Sequence Detection 
instrument and displayed as a plot of signal versus cycle number (amplification plot). In the 
initial cycles of PCR, there is little change in the fluorescence signal. This defines the baseline 
for the amplification plot. An increase in fluorescence above the baseline indicates the 
detection of accumulated PCR product. A fixed fluorescence threshold can be set above the 
baseline. The parameter CT (threshold cycle) is defined as the fractional cycle number at 
which the fluorescence passes the fixed threshold (Figure 4. 4). The CT number is inversely 
proportional to the log of initial copy number. Therefore plotting CT values versus the log of 
serial dilutions of a sample of known concentration gives a straight line. This is used as a 
standard curve from which the quantity of an unknown sample can be derived. For relative 
quantitation the CT number can be used in an arithmetic formula (Comparitive CT method). 131 
log [DNA] "" " . 
Cycle number 
FIGURE 4.2 PCR- Phases 
Exponential Phase: Exact doubling of the product at every cycle (assuming 100% reaction efficiency). 
Linear Phase: The reaction components are consumed, the reaction slows down and products start to degrade. 
Plateau Phase: The reaction has stopped, no more products are being made and, if left long enough, the PCR 
products will degrade. 
Three samples, identical in tenns of the initial amount of DNA, are considered to be amplified separately. 
Fluctuations in the quantification of the amplified DNA will be considerably larger at the end of the reaction 
than in the initial phase in which the amplification is exponential. 
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FIGURE 4.3 Cleavage of the TaqMan Probe 
The TaqMan probe consists of a high-energy reporter dye at the 5' end (R) and a low-energy molecule termed 
quencher (Q) at the 3' end; it is designed to anneal to the template between the primers. When the probe is intact 
and excited by a light source, the reporter dye's emission is suppressed by the quencher dye as a result of the 
close proximity of the dyes (A). The probe sits on the path of the Taq polymerase as it starts to replicate the 
cDNA (B). The probe is cleaved by the 5' exonuclease activity of the Taq Polymerase, so that the distance 
between the reporter and the quencher increases, causing the transfer of energy to stop. The fluorescent emission 
of the reporter dye increases and that of the quencher decreases (C). 
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FIGURE 4.4 Amplification plot 
The example depicted is merely illustrative and shows a threshold at 0.06. The threshold is set above the 
background signais and in such a way as to clearly distinguish the distinct sample amplifications, i.e. it has to 
cross the amplification plots in the exponential phase. In the actual experimental conditions the threshold was set 
at 0.02 for all experiments. 
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4.5.4 Materials and Methods for the Real-Time PCR 
DNA amplification was carried out in a final volume of 25 µl using the TaqMan® Universal 
PCR Master Mix (Applied Biosystems, PIN 4304437) according to the manufacturer's 
instructions. Primers and FAM- and TAMRA-labeled probes were purchased from Applied 
Biosystems and either chosen from the Assay by Demand catalog, with the sequences chosen 
by the manufacturer, or designed and ordered as an Assay by Design (Table 2). The master 
mix and primers were seeded into MicroAmp® Optical 96-well plates (Applied Biosystems, 
PIN 403012) under a PCR hood in the dark. 1.5 µl of cDNA ( equivalent to the RNA of 450 
cells) was added per well, and duplicates of each gene per population (Figure 4.5) were 
performed. The plate was sealed with MicroAmp® Optical Caps. The following Thermal 
Cycler conditions were used on a Taqman ABI Prism 7700 Sequence Detector: 50°C for 2 
minutes and 95°C for 10 minutes (incubation and AmpliTaq Gold enzyme activation). Bach 
run consisted of 45 cycles (of denaturing at 95°C for 15 seconds and annealing at 60°C for 1 
minute). 
1) 5' - forward primer - 3' 
GENE (human) 2) 5' - reverse primer - 3' 
3) 5' - (FAM)-probe-(TAMRA) - 3' 
1) ATGTGCAAACGCCTTCAACAA 
C-a 2) GCTTGACATCACAGGAACTTTCTG 
3) CAGCATTATTCCAGAAGACAC 
1) TGCACCTGGTTCCCATTAACG 
APRIL 2) GTTGCCACATCACCTCTGTCA 
3) CATCGGAGTCATCCTTG 
1) TGACCCCACAGCCAGAGA 
IL15-Ra 2) TGTTGTTTGAGCTGGGAGATGAAG 
3) CTGCGGGCTCTTTT 
1) GTGTGAAGGTTGGAGAAAAGAGTCT 
IL7-Ra 2) GACGACACTCAGGTCAAAAGGA 
3) ACCTAACCACTATAGTTAAACCT 
1) CCCCGACGGAGACAAGGA 
BAFF-R 2) TCAGAGATTCCCGGAGACAGAA 
3) CCCCAGAGCCCCTGGACA 
1) CAATTTCTGGTTGGAATGGTGACAA 
EPI-a 2) GGGTGACTTTCCATCCCTTGAA 
3) CCAAGGCATGTTAGCACTT 
TABLE 2 Sequences of the sets of the primers and probes ordered as Assay by Design 
C-a: gene for the constant part of the TCR-chain. APRIL: TNF-like ligand. IL-7Ra: Interleukin-7 Receptor 
chain alpha. IL-15Ra: Interleukin-15 receptor chain alpha. BAFF-R: BAFF-Receptor, TNF-like ligand 
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1 2 3 4 5 6 7 8 9 10 11 12 
A NTC NTC Posit. Posit. NTC NTC Naïve Naïve CM CM 
Contr. Contr. T7 T7 T7 T7 T7 T7 
B NTC NTC Naïve Naïve CM CM NTC NTC Naïve Naïve CM CM 
Ca Ca Ca Ca Ca Ca TS TS TS TS TS TS 
c NTC NTC Naïve Naïve CM CM NTC NTC Naïve Naïve CM CM 
Tl Tl Tl Tl Tl Tl T9 T9 T9 T9 T9 T9 
D NTC NTC Naïve Naïve CM CM NTC NTC Naïve Naïve CM CM 
T2 T2 T2 T2 T2 T.2 T 10 T 10 T 10 TlO TlO TlO 
E NTC NTC Naïve Naïve CM CM NTC NTC Naïve Naïve CM CM 
T3 T3 T3 T3 T3 T3 T11 T 11 T 11 T 11 T11 Tfl 
F NTC NTC Naïve Naïve CM CM NTC NTC Naïve Naïve CM CM 
T4 T4 T4 T4 T4 T4 T 12 T 12 T 12 T 12 T12 T 12 
G NTC NTC Naïve Naïve CM CM NTC NTC Naïve Naïve CM CM 
T5 T5 T5 T5 T5 T5 T 13 T 13 T 13 Tl3 T13 Tl3 
H NTC NTC Naïve Naïve CM CM NTC NTC Naïve Naïve CM CM 
T6 T6 T6 T6 T6 T6 T 14 T 14 T 14 T 14 T14 T 14 
FIGURE 4.5 Example of a plate setup 
NTC: no template control (no cDNA); Posit. Contr.: Positive Control; Ca: Endogenous control; Tl-Tl4: target 
genes; Naïve: Naïve T cells CM: central memory subset 
4.6 QUANTIFICATION OF GENE EXPRESSION 
A semi-quantitative approach using the Comparative Threshold-Cycle (CT)-Method131 was 
used for the quantification of target gene expression. Ca was chosen as an endogenous control 
to nonnalize the amount of target messenger RNA for differences in the amount of total RNA 
added to each reaction. The naïve T cell population was used as the basis for comparative 
results (calibrator). Each target, plus a negative control, was amplified in a separate well on a 
96-well plate. Each plate contained the amplification of the endogenous control in separate 
wells, with a negative as well as a positive control (Figure 4.4). Amplification plots were 
generated by the system, and CT-values for each well were read at a threshold level of 0.02 for 
the sample plates and at an arbitrary threshold for the dilution curves. 
Calculations were done by transcribing the CT-values on an excel-sheet. CT-values were 
averaged for each duplicate. Differences between the mean CT-values of the target gene and 
those of the endogenous control were calculated as LiCT = CT target gcne - CT c-alpha for each T 
cell subpopulation (Table 3). Differences between the L1CT-values of calibrator and memory 
cell populations were calculated as L1L1CT = LiCT naïve - CT memory for each memory cell 
subpopulation. Final results, expressed as n-fold differences of target gene expression in 
memory subpopulations relative to the naïve T cell population, were determined as 2 -(MCT). 
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T cell Average CT Average CT L1CT i1L1CT Target gene 
population of target gene of Ca gene ( CT targe! gene - (i1CT memory - relative to 
CT cat L1CT naive) b Naïve T cells c 2-(MCT) 
Naïve 30.49 ± 0.15 23.63 ± 0.09 6.86 ± 0.17 0.00 ± 0.17 1.0 
(0.9 - 1.1) 
CM 27.03 ± 0.06 22.66 ± 0.08 4.37 ± 0.10 -2.50 ± 0.10 5.6 
(5.3 - 6.0) 
EM 26.25 ± 0.07 26.60 ± 0.07 1.65 ± 0.10 -5.21±0.10 37.0 
(34.5 - 39.7) 
TEM 25.83 ± 0.07 23.01±0.07 2.81±0.10 -4.05 ± 0.10 16.5 
(15.4-17.7) 
TABLE 3 Example of Relative Quantification using the Comparative CT Method 
a: The standard deviation fi·om the LJCT-value is ca!cu!ated as s = -,_f (s/ + s/). b: The calculation of the L1L1CT-
value invo!ves subtraction of an arbitrmJ1 constant (ca!ibrat01), so that the standard deviation of L1L1CT is the 
same as that of L1 CT. c: The range for the final result is determined by evaluating 2 - (,ucr; with L1L1 CT + s and 
L1L1CT-s. 
Note: The numbers are taken ji'Oln the User Bulletin no.2 (Applied Biosystems) and used as an illustration. 
4. 7 STIMULATION EXPERIMENTS 
4.7.1 Polyclonal stimulation with anti-CD3 and anti-CD28 
A 96-well flat bottom culture plate was first coated with anti-CD3 diluted in PBS at 1 µg/ml 
(100 µl per well) and incubated at 4°C overnight. Excess antibody was removed by washing 
the plate twice with sterile PBS. Cells were stained, sorted, counted and re-suspended in cell 
culture medium containing 2% AB-Serum and lµg/ml of anti-CD28 (unc011}ugated mouse-
anti-human CD28, 0.5mg/m1, BD Pharmingen) at a concentration of 100'000 cells per 100 ~tl. 
200'000 cells per well were incubated at 37°C with 5% C02. At each time-point (Oh, 24h, 48 
h, 72h), cells were collected and resuspended in PBS-2% FBS. Viable cells were gated, and 
15'000 cells were sorted by FACS Vantage into Eppendorffs. RNA was extracted 
immediately. 
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4.7.2 Homeostatic stimulation assay 
A mix of the five cytokines, IL-7, IL-15, IL-10, IL- 6 and TNFa, is known to induce 
homeostatic proliferation in human T cells. We used the same conditions as previously 
published by Sallusto et al. 141 
The cytokine mix (IL- 6, IL-7, IL-15, IL-10 and TNFa: recombinant human cytokines, R&D 
Systems) was prepared at a concentration of 50 ng per ml for each cytokine in RPMI 2% AB-
Serum and used to seed a 96-U-bottom culture plate with 100 µl per well. Cells were stained, 
sorted, counted and re-suspended in RPMI 2% AB-Serum at 500'000 cells per ml. 1 OO µl of 
cells were added to each well, thus obtaining 100'000 cells per well in a culture medium 
containing 25 ng per ml of each cytokine. Cells were incubated at 37°C with 5% C02, 
collected at 4 time points (day 5, 7, 9, 12) and re-suspended in PBS-2% FBS. Viable cells 
were gated by flow cytometry, and 15'000 cells were sorted by F ACS Vantage into 
Eppendorffs. RNA was extracted immediately. 
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5 VALIDATIONOFTHEASSAY 
5.1 VALIDATION OF THE ENDOGENOUS REFERENCE GENE 
Real-time reverse transcription (RT)-PCR131 -133 is currently one of the most sensitive methods 
for the detection of low-abundance mRNAs and quantification of genes with low expression 
levels. Quantification can either be absolute or semi-quantitative. In the semi-quantitative 
approach, the mRNA level of a standard in the sample can be used to normalize the 
expression level of a selected target gene. This normalization is often performed by measuring 
the nucleic acid level of an external reference molecule. However, the preparation and 
inclusion of synthetic DNA or RNA standards does not account for manipulations of the 
sample before addition of the standard. Therefore, an endogenous reference gene exposed to 
the same manipulations as the target gene prior to quantification, is a more natural choice. For 
this purpose, the expression of a constitutively expressed endogenous gene (or housekeeping 
gene) in the same sample is often monitored. 
The ideal internal standard, or endogenous control, 134 has the following characteristics: 
• When analyzing different donors, the control presents an intra- and inter-donor 
consistency in its expression. 
• The standard should be expressed at constant levels within the cell subsets under 
analysis (target population consistency). 
• It should be expressed at roughly the same level as the RNA under study (target gene 
equivalency). 
• Its expression should remain unaffected by the experimental treatment (preservation of 
expression). 
Three possible internal controls have been examined: 
1) Ca: Ca designates the constant domain of the a-chain of the aP-T-cell-receptor 
and is expressed specifically on virtually all peripheral human T cells (Figure 
5.1). 
2) Beta-2-microglobulin (B2m): p2m is the small subunit of the MHC class I 
molecule and is associated with the outer membrane of many cells of the body, 
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including lymphocytes. It is a house-keeping gene that is commonly used as an 
internal control in semi-quantitative gene analysis. 
3) Elongation factor-la (EF-la): EF-la has been shown to be stable during 
human CD4+ T cell differentiation by comparing its expression in naïve 
human CD4+ T cells to that of in vitro activated T cells. 134 
Va 
Ca 
FIGURE 5.1 The T-cell-Receptor (TcR) 
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The TcR is a heterodimer with a molecular weight of~ 85,000 - 90,000 D. lt is composed of either alpha and 
beta, or gamma and delta, polypeptide chains. The alpha/beta TcR is present on more than 95% of peripheral T 
cells. Each chain has a variable region domain and a constant region domain (designated Vu and Ca, vp and 
cp, respectively). The variable region domains of the alpha and beta chains corne together to form the antigen 
binding cleft. (Figure and text adaptedfrom the Westem Kentucky University Biology course). 
To test the consistency of the expression of the control genes within a single donor (intra-
donor consistency), RNA from an equivalent amount of cells was extracted seven times from 
three different donors and tested for the expression level of the control gene. The Ca-gene 
was found to present highly consistent intra-donor expression levels, as only very slight 
variations of the CT-levels were found in all three cases (Figure 5.2). 
Further, the consistency of the control gene expression between different donors was analyzed 
(inter-donor consistency). For this purpose, dilution curves were created for different 
individuals. Total RNA was extracted for each individual on a separate mini-column and 
quantified by a spectrometer. 1 OO ng of RNA was diluted 4 times. Individual cDNA was 
prepared with each dilution, which was subsequently analyzed for the control gene 
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express10n. Expression levels of the Ca-gene were found to be significantly consistent 
amongst different donors as the dilution curves were virtually identical (Figure 5.3). 
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FIGURE 5.2 Intra-donor consistency of the endogenous control gene 
Ca expression on 100 CD4+ T cells in 3 different individuals (LHD 190, LHD 179 and LHD 177). In each case, 
the depicted Cr value corresponds to the average value of 7 duplicates, the red error bar indicating the 
corresponding standard deviation. 
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FIGURE 5.3 Inter-donor consistency of the endogenous control gene 
Ca RNA dilution curves for 2 different individuals (LHD 165 and LHD 167). The dilution curves of the two 
individuals are nearly identical. 
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To test whether the endogenous control was expressed constantly amongst the cell subsets to 
be compared (target population consistency), the different memory T cell subsets were sorted 
individually and analyzed for the expression of the control gene. The CT values of each 
subpopulation for each control gene were plotted as a trend line. The consistency of the 
intemal standard was evaluated by measuring the slope of this trend line. The more the slope 
approaches zero, the more consistent is the expression levels of the control gene amongst the 
different subsets (Figure 5.4). The slope of the trend line for Ca was closer to zero (0.075) in 
the CDS+ memory subsets, as compared to that for B2m (0.188). 
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FIGURE 5.4 Target population consistency 
Expression levels of Ca and Beta-2-microglobulin in CD8+ T memory cell populations. The consistency of the 
gene expression amongst the 4 subpopulations is reflected by the slope of the trend line being close to zero. 
Blue: Trend line for Ca, slope: 0.075. Orange: Trend-line for ~2m, slope: 0.188. The value for each 
subpopulation corresponds to the average of 4 different individuals with 2 duplicates per gene. 
Naïve: CD8+ CD45RA+ CCR7+ cells. CM (central memory subset): CD8+ 45RA- CCR7+. EM (effector memory 
subset): CD8+ 45RA-CCRT. TEM (terminal effector memory subset): CD8+ 45RA+ CCRT. 
Ideally, the intemal standard should express mRNA levels similar to those of the target gene 
(target gene equivalency). In the case of this study, the target genes were all expressed at low 
levels. The tested references, EF-la and B2m, however, were both expressed at significantly 
higher levels than the target genes. The Ca-gene, on the other hand, expressed approximately 
the same amount of mRNA as the target genes, thus being the only of the three tested 
references to fulfill the required condition. This was tested experimentally by analyzing the 
expression of the three reference genes from equivalent RNA amounts of a given donor. 
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CT values of each endogenous control gene were compared to the expression of the target 
gene on the same sample of the same donor. These results were confirmed in three different 
donors (Figure 5. 5). 
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FIGURE 5.5 Expression levels of endogenous control genes compared to target gene 
Ca (b!ue diamonds) is expressed at similar levels as the target gene Tob (orange triangles). EF-1 a (green 
circ/es) amplified at lower Cy values than the target gene. Duplicates for each gene were performed in each 
donor. Tob is depicted as an example for the target genes. The RNA content in this particular experiment was not 
the same for the individual donors 
Another important aspect of the interna! standard is its constant expression when subjected to 
different experimental conditions (preservation of expression). The following two 
experimental conditions were tested: 
a) homeostatic proliferation in T cells (Figure 5. 6) 
b) polyclonal stimulation by anti-CD3 and anti-CD28 antibodies (Figure 5. 7) 
For this purpose, total CD4+ T cells were incubated either (a) with a cytokine mix consisting 
ofIL-6, IL-7, IL-10, IL-15 and TNFa for a total of nine days, or (b) with anti-CD28 antibody 
in anti-CD3 coated culture plates for a total of 6 days. Samples with equivalent cell numbers 
were collected from 4 time-points for each experiment and analyzed for the reference gene 
expression. The CT values of the time-points of each experiment were plotted as a trend line 
for each control. The consistency of expression was determined by analyzing the slope of the 
trend line. The trend line for Ca demonstrated a slope close to zero in both the experimental 
conditions for two different individuals tested (Figure 5.6 and Figure 5. 7). 
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FIGURE 5.6 Ca expression during homeostatic stimulation of total CD4+ T cells 
Ca expression in total CD4+ of two different individuals (LHD 177 and 179) was analyzed at day 0, 3, 6 and 9 of 
homeostatic proliferation induced by cytokines. The slope of the trend lines ofboth the subjects tested was close 
to zero. (Green: LHD 177; slope: 0.297. Orange: LHD 179; slope 0.389). 
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FIGURE 5.7 C alpha expression during polyclonal stimulation of total CD4+ T cells 
Ca expression in total CD4+ of two different individuals (LHD 177 and 179) was analyzed at 0, 48, 72 and 144 
hours of polyclonal proliferation induced by anti-CD3 and anti-CD28 antibodies. The slope of the trend lines of 
both the subjects tested was close to zero. (Green: LHD 177; slope: 0.039. Orange: LHD 179; slope 0.041). 
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5.2 VALIDATION OF THE PCR REACTIONS 
In an ideal PCR reaction, 135 a two-fold doubling of amplicon occurs at each cycle, which 
corresponds to a 100% efficiency of the reaction. The kinetics of a PCR reaction can be 
expressed by the following equation: 
Rn = Ro x (1 + E)17 ... (1) 
where. Rn is the number of template molecules at cycle n and R0 coITesponds to the initial 
number of template molecules. E is the PCR efficiency (0 :SE :S 1; if E = 1, the efficiency of 
the reaction is 100%). 
The efficiency of the real-time PCR reaction can be calculated by the following relation: 
E = 10C-llm) - 1 
... (2) 
where m is the slope of a dilution curve established by tenfold dilutions. In order to obtain 
accurate and reproducible results, reactions should have an efficiency as close to 100% as 
possible (m = 3.32). Thus, the efficiency of the PCR should be 90-100% (3.6 > m > 3.1). A 
number of variables can affect the efficiency of the PCR. These factors include length of the 
amplicon, presence of inhibitors, secondary structure and primer design. Although valid data 
can be obtained that fall outside of the above efficiency range, the qRT-PCR- reaction should 
be further optimised, or alternative primers designed, in case E < 0.90. 
To test the amplification efficiencies for the individual primers, dilution curves were prepared 
using stock RNA extracted from total PBMC. The total RNA was quantified by a 
spectrometer, and tenfold dilutions ranging from 0.001 ng to 100 ng were used for the 
subsequent cDNA preparations. Individual cDNA preparations for each target gene were 
subsequently used for amplification of all the target genes and the reference gene. Cy values 
were plotted against log RNA amount (Figures 5.8 and 5.9). The slopes of these dilution 
curves were given by the curve equation. All the primers could be amplified with an 
efficiency superior to 90%, since the values for all the slopes were 3.6 > m > 3.1 (Table 4). 
Since each of the dilutions was prepared prior to cDNA preparation, possible variations 
occuITing during the reverse transcription step, as well as during manipulation (pipetting), 
could be considered negligible, the rectitude values of the dilution curves being all superior to 
0.99 (Table 4). 
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FIGURE 5.8 RNA dilution curve for IL-7-Rn and C alpha 
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elL7-Ra 
ec alpha 
IL7-Ra y= -3.15x + 26.3 
R2 = 0.9962 
Calpha y= -3.22x + 27.8 
R2 = 0.9995 
IL7-Ra is depicted as an example of the various primers designed and purchased as "Assays by Design" from 
Applied Biosystems. These include: Baff-R, Ca, IL15-Ra, IL7-Ra, APRIL and EF-la. 
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FIGURE 5.9 RNA dilution curve for Bcl-2 and C alpha 
3 4 
0 Bcl-2 
e C alpha 
Bcl-2 y= -3.31x + 28.7 
R2 = 0.9968 
C alpha y= -3.22x + 27.8 
R2 = 0.9995 
Bcl-2 is depicted as an example of the various pre-designed primers, purchased as "Assays on Demand" from 
Applied Biosystems. These include: Bcl-2, Bcl-xL, Bad, Bax, Flip, Tob, Baff, Taci, FasL and ~2m. 
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GENE SLOPE RECTITUDE 
m R2 
CALPHA -3.216 0.9995 
BCL-2 -3.303 0.9968 
FLIP -3.263 0.9927 
BAD -3.248 0.9950 
TOB -3.532 0.9958 
APRIL -3.358 0.9992 
IL15-Ra -3.420 0.9997 
IL7-Ra -3.152 0.9962 
TACT -3.392 0.9978 
BAFF -3.126 0.9975 
BCMA -3.506 0.9995 
FAS-L -3.414 0.9909 
BCL-XL -3.348 0.9969 
BAX -3.488 0.9985 
BAFF-R -3.119 0.9976 
EF-la -3.269 0.9941 
TABLE 4 PCR efficiency 
RNA dilution curves were established for each primer pair. The slope of each individual curve allowed 
estimation of the PCR efficiency. Ail the primers could be amplified with an efficiency superior to 90%, since 
their slope values were between 3.6 and 3.1. 
In order to test the purity of the primer pairs, a RT-minus control was performed for all the 
target genes and the reference gene. The RT-minus control consists of a sample cDNA which 
is synthesized without the presence of RTase, e.g. the enzyme that enables reverse-
transcription of RNA to DNA. This control cDNA can then be used in the normal semi-nested 
PCR. If the RT-minus control is negative, there is no contaminating DNA in the sample used 
(Figure 5.10). 
Negative -RT 
FIGURE 5.10 RT-minus control for Ca visualized on an agarose-gel 
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5.3 VALIDATION OF THE COMPARATIVE CT METHOD 
In the case of a semi-quantitative analysis, 136-139 both target and reference ( endogenous 
control) should have similar efficiencies. The comparative CT method used in this study, and 
previously described by Livak, 136 detects the relative gene expression with the formula r',LiCT. 
This formulais based on the following two assumptions: 
(1) Amplification efficiency should be close to 100% 
(2) Amplification efficiencies of the target gene and of the reference gene must be 
approximately equal. 
Thus, the comparative CT method used in this study can only be applied when both these 
requirements are fulfilled. As discussed in the previous chapter, all the primers presented 
amplification efficiencies between 90-100% (Table 4). To test whether the second 
requirement was valid for the internai standard selected for this study (Ca), efficiencies of all 
the target genes of the gene panel had to be compared to the amplification efficiency of the 
Ca primers. 
A sensitive method for assessing whether two amplicons have the same efficiency is to 
examine how their L1CT varies with template dilution (relative efficiency plot). For this 
purpose, the L1CT of the target gene and Ca can be plotted against the log template amount and 
the relative efficiency estimated by analyzing the slope of the thus generated tendency curve. 
Ideally, the slope should equal 0, implying that the target gene and Ca have identical 
amplification efficiencies. Thus, if the absolute value of the slope (c) is < 0.1, the 2-MCT 
formula can be applied (Figure 5.11). 
In practical terms, this also means that the L1L1CT calculation can be used for a given target 
gene without running standard curves on the same plate. The validation experiment was 
performed for all the primer pairs. Since the efficiencies of all the target genes were shown to 
be approximately equal to that of Ca (c < 0.1; Table 5) the L1L1CT calculation could be applied 
to the entire gene panel. 
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FIGURE 5.11 Relative efficiency plot for IL 7-Ra and Ca. 
The values from the RNA dilution curves of Ca and IL 7-Ra were used to obtain the delta Cy value: LiCT = LiCT 
(Ca) - LiCT (IL 7-Ra). The slope is < 0.1 (c = 0.064), indicating that the amplification efficiencies of Ca and IL 7-
Ra are sufficiently close to allow the use of the comparative Cy method. 
TABLE 5 
EQUATION 
IL15-Ra 
IL7-Ra 
FAS-L 
FLIP 
TOB 
SLOPE 
Delta Gr ene- Ca) 
0.08 
-0.08 
0.03 
0.05 
0.05 
-0.007 
-0.09 
0.06 
0.09 
-0.06 
0.06 
-0.03 
0.06 
Relative efficiencies of target genes versus Ca. 
The values of the RNA dilution curves were used to plot the delta CT values of each target gene minus the 
internal control (Ca), versus log RNA (template). The equation for the straight-line fit obtained and the 
corresponding slope value are listed for each individual gene. The slopes are seen to be all < 0.1, implying that 
the comparative Cy method can be applied reliably to calculate relative mRNA expression as compared to Ca 
expression. 
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6 RESULTS 
The leucocyte filters of healthy blood donors from the regional blood bank were used to 
obtain total PBMC, which were then screened for the expression of CD4 and CD8. The total 
PBMC of 4 donors (LHD 234, LHD 275, LHD 283 and LHD 288) were sorted according to 
their surface expression of CD8, CD45RA and CCR7; 3 donors were sorted for CD4, 
CD45RA and CCR7 (LHD 216, LHD 283 and LHD 288). The expression of a total of 15 
genes, including the endogenous control gene (Ca), was analyzed separately in naïve CD4+ 
and CD8+ T cells, as well as in the three corresponding, individually sorted memory subsets. 
o "CM" correspond to central memory cells characterized by a CD45RA-CCR 7+ 
phenotype. 
o "EM" are effector memory cells with a CD45RA-CCR T phenotype. 
o "TEM" are terminally differentiated effector memory cells with a CD45RA+CCRT 
phenotype. 
Gene expression was assessed using cDNA corresponding to total mRNA from 450 cells per 
population and gene. Semi-quantitative analysis was based on the comparative CT Method, 
using Ca as an endogenous control and the naïve population as the calibrator. Ca 
amplification was performed on the same cDNA and in parallel to target gene amplification, 
on the same plate. The calculation as a whole was first performed for each individual. The 
relative expression of each gene was then averaged for each population and presented 
graphically. 140 The results are presented as gene expression in a memory subset, relative to 
gene expression in the corresponding naïve T cell population. This implies that: 
• Results superior to 1 mean that the gene expression levels in that particular memory 
subpopulation are higher than expression levels in naïve cells. 
• Results equal to 1 mean that the gene is expressed in equal amounts in the analyzed 
memory subset and in naïve cells. 
• Results infèrior to 1 mean that the expression levels of that gene are lower in the 
particular memory subset than in the respective naïve cell population. 
49 
Results 
6.1 Survival genes: BAFF, APRIL and their RECEPTORS 
In the CDS+ rnernory subsets, BAFF expression levels were quite variable frorn one 
individual to another, as indicated by the substantial standard deviations (Figure 6.JA). 
However, on average, expression levels vary rnoderately frorn the expression level in naïve 
CDS+ T cells. In contrast, the CD4+ rnernory subsets were all shown to upregulate BAFF 
expression - reaching up to three tirnes the level of expression of naïve CD4+ cells in the 
central rnernory population (Figure 6.JB). 
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6.lA. BAFF expression in CDS+ memory T cell subsets. The CD45RA-CCR7- (EM) subset expresses the 
highest levels of BAFF mRNA, with levels up to 1.8 times the levels of expression in naïve cells (LHD 288). 
6.lB. BAFF expression in CD4+ memory T cell subsets. Ali 3 individuals expressed higher levels of BAFF 
mRNA the memory subsets, as compared to naïve CD4+ cells. The highest upregulation was in the CM subset 
with up to 3.4 times the levels (LHD 283). 
The expression of the other ligand, APRIL, on the other hand, is clearly downregulated in all 
CDS+ rnernory cell subsets (Figure 6.2A). In CD4, on the other hand, the CD45RA-CCR7+ 
(TcM) and CD45RA-CCRT (TEM) subsets express levels of APRIL that are more or less 
equivalent to those of the naïve population. The CD4+ CD45RA+CCRT (TrnM) population 
however, seerns to upregulate APRIL rnRNA (Figure 6.2B). 
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Figure 6.2 
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6.2A. APRIL expression in CDS+ memory T cell subsets. APRlL mRNA was present in lower levels in all the 
three memory CDS subsets. Lowest levels were found in the CD45RA-CCR7- (EM) and CD45RA+CCR7-
(TEM) subsets. Expression levels were as low as 23% ofmRNA levels in naïve cells. 
6.2B. APRIL expression in CD4+ memory T cell subsets. The CD45RA+CCR7- (TEM) subset was the only 
subset to express higher levels of mRNA than naïve cells. This was consistent in the 3 individuals tested. The 
highest levels of APRlL mRNA were 3.5 tünes higher than levels in naïve cells (LHD 283). 
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6.3A. BAFF-R expression in CDS+ memory T cell subsets. Relative Baff-R expression was lower in the 
memory subsets for all individuals, except for LHD 234 who expressed 1.4 tünes higher levels of mRNA in the 
CD45RA-CCR7+ (CM) subset only. The weakest expression was within the CD45RA+CCR7- (TEM) subset, 
with levels as low as 4.5% (LHD 288). 
6.3B. BAFF-R expression in CD4+ memory T cell subsets. In all the 3 individuals, Baff-R mRNA least 
expressed in the CD45RA-CCR7- (EM) subset and most expressed in the CD45RA+CCR7- (TEM) subset, in 
which levels were as high as 3.4 times as high as in naïve CD4+ cells (LHD 216). 
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When considering the expression of the BAFF and APRIL receptors, it should be noted that 
TAC! and BCMA were never detected in naïve or memory CD4, or in any CD8 T cells during 
this study (data not shown). Therefore, importantly, the only receptor found to be expressed 
consistently in our experimental conditions, is BAFF-R which is known to be specific to 
BAFF. In CD8+ T cells, BAFF-R mRNA is clearly expressed at lower levels in memory cells 
than in naïve cells. This downregulation seems to increase with the differentiation to a more 
effector phenotype memory cell (Figure 6.3A). Contrarily, in CD4+ memory subpopulations, 
BAFF-R expression levels are higher than in the naïve population, except for the CD4+ 
CD45RkCCRT (TEM) subset (Figure 6.3B). 
6.2 Survival genes: IL-15-RECEPTOR and IL-7-RECEPTOR 
The IL-15Ra expression in CD8+ T cells was shown to be quite variable from one individual 
to another in all the memory subsets. The CD8+CD45RkCCRT (TEM) subset, however, 
seems to preferentially upregulate IL-15Ra mRNA levels in CD8 T cells (Figure 6.4A). In 
CD4+ memory T cells, the general expression levels of IL-15Ra seem to be slightly higher 
than expression in naïve CD4+ cells. The CD4+CD45RA+CCRT (TTEM) subpopulation 
showed a very variable expression amongst the individuals tested with sometimes very high 
levels (Figure 6. 4 B). 
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6.4A. IL-15Ra expression in CDS+ memory T cell subsets. The CD45RA-CCR7- (EM) subset expressed the 
highest levels IL-15Ra, with levels up till 3. 7 tünes the levels of expression in naïve CDS+ cells (LHD 283). 
6.4B. IL-15Ra expression in CD4+ memory T cell subsets. IL-15Ra expression was generally higher in the 
memory subsets in all individuals, but expression in the CD45RA+CCR7- (TEM) subset varied extensively 
between the individuals. LHD 283 expressed 5.5 tünes higher levels in the TEM subset. 
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As regards the expression of the IL-7Ra gene, only the CD45RA-CCR7+ (TcM) subset of 
memory CDS+ T cells was found to express higher levels of IL-7Ra transcripts than naïve 
CDS+ cells. In both the effector memory subsets, IL-7Ra mRNA was downregulated, 
moderately in CDS+CD45RA-CCRT (TEM) cells and much more strongly in the 
CDS+CD45RA+CCRT (TTEM) subpopulation (Figure 6.5A). In CD4+ T cells, all the memory 
subsets expressed lower levels of IL-7Ra mRNA as compared to naïve CD4+ T cells, with a 
tendency to greater downregulation in the most terminally differentiated subtype (Figure 
6.5B). 
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6.SA. IL-7Ru expression in CDS+ memory T cell subsets. In 3 out of the 4 individuals, IL-7Ra levels were 
higher in the CM population (up to 1.8 tiines) and lower in the EM subset. All 4 individuals expressed the lowest 
levels in the TEM subset (up to 0.05 tünes). 
6.SB. IL-7Ru expression in CD4+ memory T cell subsets. IL-7Ra levels were virtually lower in all the 
memory CD4 subsets for the 3 individuals. The TEM subset expressed the lowest levels of IL-7Ra mRNA (up to 
0.3 titnes lower than naïve CD4 cells). 
6.3 ANTI-APOPTOTIC GENES 
The expression of the Bcl-2 gene was significantly downregulated in all the three CDS+ T cell 
memory subsets. The levels decreased with further differentiation towards an effector 
phenotype (Figure 6.6A). In the CD4+ cells, the Bcl-2 mRNA levels varied substantially from 
one individual to another, and no tendency could be demonstrated for any of the subsets 
(Figure 6.6B). 
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Figure 6.6 
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6.6A. Bcl-2 expression in CDS+ memory T cell subsets. Bcl-2 levels were clearly lower in all the CDS memory 
subsets than expression in naïve CDS. This was very consistent in all the 4 individuals. Lowest relative mRNA 
levels (minimum 0.13 for LHD2SS) were present in the TEM population. 
6.6B. Bcl-2 expression in CD4+ memory T cell subsets. Bcl-2 expression was variable amongst the 3 
individuals. The greatest variations were observed for the TEM subset. 
Bcl-xL mRNA was present in greater arnounts in all subsets of rnernory T cells, both for 
CDS+ and CD4+ populations. Especially in CDS+ rnernory T cells, the expression levels were 
clearly increased in the four individuals exarnined. The more effector phenotype subsets (T EM 
and T TEM) had significantly higher expression levels as cornpared to the central rnernory, 
CDS+CD45RA-CCR 7+ (T cM) subset (Figure 6. 7 A). In CD4+ cells, the T EM consistently 
showed the highest level of expression in all the individuals exarnined (Figure 6. 7B). 
The expression of the FLIP gene was found to be upregulated in all the three rnernory subsets 
of CDS+ T cells. The terrninally differentiated effector subset (CD45RA+CCRT, TrnM), 
however, showed the highest levels of FLIP rnRNA (Figure 6.8A). In the CD4+ population, 
on the other hand, FLIP expression levels were downregulated in all the rnernory subsets 
(Figure 6.8B). 
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Figure 6.7 
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6.7A. Bcl-xL expression in CDS+ memory T cell subsets. Bcl-xL mRNA levels were generally higher in all the 
CDS memory subsets as compared to naïve CDS cells. Significantly high levels, with up to 3.3-fold increase, 
were observed in the CD45RA +CCR 7- (TEM) subset. 
6.7B. Bcl-xL expression in CD4+ memory T cell subsets. In CD4 cells, Bcl-xL expression was moderately 
upregulated in all subsets, but consistently highest in the CD45RA-CCR7- (EM) subset. 
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6.SA. FLIP expression in CDS+ memory T cell subsets. Even though all the CDS memory subsets expressed 
more FLIP mRNA than naïve cells, the highest levels were clearly present in the CD45RA+CCR7- (TEM) 
subset, with relative levels as high as 2.7 tiines expression levels in naïve cells. 
6.SB. FLIP expression in CD4+ memory T cell subsets. In the three individuals analyzed, FLIP mRNA levels 
were slightly lower in all the three memo1y subpopulations of CD4+ T cells as compared to expression in naïve 
CD4+ cells. 
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6.4 PRO-APOPTOTIC GENES 
Expression of the pro-apoptotic gene Bad within the CDS+ memory T cell compartment was 
extremely heterogeneous in the four individuals analyzed (Figure 6.9A). In CD4+ memory T 
cells, Bad expression showed much less inter-individual variability (Figure 6.9B). In both 
CD4+ and CDS+ memory cells, average mRNA levels were quite close to those of naïve T 
cells. 
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6.9A. Bad expression in CDS+ memory T cell subsets. Bad expression in CDS memory T cells was variable 
amongst the four individuals tested. The lowest levels were found in the effector memory subsets. 
6.9B. Bad expression in CD4+ memory T cell subsets. Expression in memory CD4+ T cells varied only slightly 
from expression in naïve CD4+ cells. The CD45RA-CCR7+ (CM) population, however, consistently presented 
moderately higher Bad mRNA levels than naïve CD4+ cells. 
Bax mRNA levels were shown to be heterogeneously expressed amongst the donors analyzed, 
resulting in a high inter-individual variability in both CDS+ and CD4+ memory T cells. In the 
CDS+ T cell compartment, Bax expression was generally downregulated in all the memory 
subsets (Figure 6.1 OA). In contrast, Bax mRNA levels were clearly upregulated in all the 
CD4+ memory T cell subsets (Figure 6.lOB). 
FasL gene expression was found to be absent in naïve cells of both the CD4 and CDS T cell 
compartments. In memory T cells, FasL mRNA levels were highly upregulated in 
increasingly differentiated effector subpopulations of CDS+ memory T cells (Figure 6.1 lA). 
In CD4+ cells, however, FasL expression was only found in the terminally differentiated 
CD45RA + CCR T subset (Figure 6.11 B). 
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6.lOA. Bax expression in CDS+ memory T cell subsets. Bax expression was generally lower in all the CD8 
memory subsets. This was the most consistent in the CD45RA-CCR7+ (CM) subset, where all the 4 individuals 
expressed the lowest levels of Bax mRNA. 
6.lOB. Bax expression in CD4+ memory T cell subsets. For CD4+ T cells, Bax mRNA was present in higher 
levels in all the memory subsets. The greatest expression was observed in the CD45RA-CCR7- (EM) subset, 
with levels as high as 3.4 times the expression levels in naïve CD4 cells. 
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6.1 lA. FasL expression in CDS+ memory T cell subsets. FasL expression was not observed in the naïve CD8 
cells of any of the 4 individuals. FasL mRNA was highly upregulated from one subset to another, with the 
highest amounts in the TEM subset. LHD 288, for example, expressed approximately 11 titnes more FasL in the 
EM subset and 28 times more in the TEM subset than in the CM cells. 
6.llB. FasL expression in CD4+ memory T cell subsets. FasL mRNA was only detected in the 
CD45RA+CCR7- (TEM) subset of CD4+ T cells in the 3 individuals tested. A semi-quantitative analysis could 
therefore not be performed. In the figure, the depiction of the presence of FasL in the TEM population is purely 
symbolic. 
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6.5 Anti-proliferation gene: TOB 
In the CD8+ T cell compartment, Tob mRNA levels were found to be constantly 
downregulated in all the memory subpopulations. Moreover, downregulation correlated with a 
differentiation towards a more effector-type phenotype (Figure 6. l 2A). Contrarily, in CD4+ 
cells, expression levels were variable amongst the individuals analyzed, and average mRNA 
levels in the different memory cells remained close to mRNA levels of naïve CD4+ T cells 
(Figure 6. l 2B). 
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6.12A. Tob expression in CDS+ memory T cell subsets. Tob mRNA was clearly present in lower levels for the 
3 subpopulations of memory CDS T cells as compared to naïve cells, in all the 4 individuals analyzed. Relative 
expression was as low as 0.16 in the TEM subset (LHD 288). 
6.12B. Tob expression in CD4+ memory T cell subsets. In the CD4+ T cells, Tob expression amongst the 3 
individuals was quite variable for the EM and TEM subsets. Generally, expression levels in all the memory 
subsets were only moderately different from expression levels in naïve cells. 
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7 DISCUSSION 
Memory T cells are generally considered to be more resistant to apoptosis than naïve T cells. 
For example, the reduction of naïve cells is 8-fold greater than that of memory cells after 
whole body irradiation. 142 However, recent research has emphasized the heterogeneity of 
memory T cells and the existence of distinct subpopulations which differ not only in their 
effector functions, but also in their ability to survive. Many genes have been attributed roles in 
the survival and death pathways of human T cells, but their individual importance is poorly 
understood. 
This study aims at helping identify the genes that play pivotal roles in the maintenance of 
long-lived human T cell populations and at increasing the understanding of regulation of 
survival and apoptosis in memory T cells. In this context, gene expression patterns been 
differentially studied in the individual memory cell subsets. Additionally, expression patterns 
have been compared between CD4 and CD8 memory T cells. Technically, the approach has 
consisted of (a) flow-cytometric sorting of three mem01y subpopulations separately in CD4 
and CD8 positive T cells (according to their expression of CD45RA isoform and the 
chemokine receptor CCR7) and (b) study of gene-expression by real-time PCR. A panel of 14 
genes potentially involved in survival and apoptosis of T cells has been analyzed. The 
obtained gene expression results, as well as possible implications of the expression pattern in 
the immune response, are discussed separately below for each gene. 
It should be mentioned that the reported results, as well as the conclusions drawn, need 
confirmation through corroborative protein or functional data. Such experimental validation, 
however, falls beyond the scope of the current research. 
BAFF, APRIL and their receptors 
As mentioned earlier, the expression of these TNF-like-ligands and their receptors has been 
poorly studied in T cells. In fact, their expression in T cells has been quite controversial83 '85 ' 143 
and previous studies have actually refrained from showing expression of BAFF or APRIL in 
human T cells. The results obtained here, however, clearly demonstrate the presence of BAFF 
and APRIL mRNA in human T cells. The presence of BAFF and APRIL gene expression has 
not only been confirmed in total T cells (preliminary experiments, data not shown), but also 
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separately in naïve as well as memory CD4+ and CDS+ T cells. For the first time, the mRNA 
expression of these ligands is now documented in the individual T cM, T EM, and T TEM memory 
subpopulations. Even though no absolute quantitative analysis has been performed, the high 
CT numbers indicate that the expression level of the two ligands is probably quite low in 
resting human T cells. This may have been one of the reasons why other studies have failed to 
show any expression at all, possibly due to experimental limitations with techniques such as 
Northern Blots that are less sensitive than RT-PCR. 
From the obtained results, one can draw the following conclusions concerning the expression 
of BAFF and its receptors in memory human T cells: 
GD CD4+ memory T cells express higher levels of BAFF mRNA than naïve CD4+ cells; 
the expression in CDS+ memory cells however is variable. 
GD The receptors TACI and BCMA are not expressed in naïve or memory human T cells. 
GD BAFF-R expression is more differentially regulated in CDS+ cells as compared to 
CD4+ cells. In CDS+ memory T cells, BAFF-R mRNA levels decrease with increasing 
differentiation towards an effector memory phenotype, whereas in CD4+ only the 
effector-memory subset shows a slightly downregulated expression. 
The previously unrep~rted expression of BAFF-R transcripts in human T cells indicates a 
potential new role of BAFF-BAFF-R signaling specific to T cells. This has to be confirmed 
by showing BAFF-R surface expression on T cells. Since expression levels of BAFF-R have 
been found to be downregulated in effector phenotype memory cells, BAFF-BAFF-R 
signaling may be implicated in T cell survival and memory maintenance independent of 
antigen. This can be considered as quite striking, since the binding of BAFF to BAFF-R has 
been attributed a crncial and somewhat exclusive role in B-cell maturation and homeostasis. 93 
But in any case, the expression of this receptor in T cells suggests other implications and 
functions of BAFF / BAFF-R interaction, yet to be elucidated. 
Concerning the expression of APRIL and its receptors, this study shows that in memory 
human T cells: 
GD All CDS+ memory T cell subsets downregulate APRIL mRNA. 
GD In CD4+ memory T cells, only the CD4+ CD45RA+CCRT (TrnM) population 
upregulates APRIL gene expression. 
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• The genes of the receptors TACI and BCMA are not expressed. 
In general, naïve cells apparently express higher levels of APRIL mRNA than memory T 
cells. Since even the naïve CD45RA+CCR7+ population wasn't found to express either TACI 
or BCMA, one can conclude that either APRIL expressed by T cells doesn't influence normal 
human T cell populations in an autocrine or paracrine manner, or that T cells express a yet to 
be discovered specific receptor to APRIL. Supporting the existence of an additional APRIL 
receptor is the fact that the Jurkat human leukemia T cell line, which is highly susceptible to 
APRIL stimulation, does not contain detectable levels ofTACI or BCMA mRNA.99 
Considering, however, that APRIL expression is most clearly downregulated in the CD8 
memory population (which is the "executor" arm of cell-mediated immunity), it is reasonable 
to argue that APRIL probably doesn't influence the T cell mediated immune response directly. 
The upregulation of APRIL in the most differentiated phenotype of CD4 memory cell 
populations, however, could point to a role for this molecule in T cell-dependent B cell 
responses, such as the elicitation of an efficient humoral immune response. Similarly, a 
recently published paper reported APRIL expression in activated Thl or Th2 cells, but not in 
naive cells. 99 One should note that another study also demonstrated the importance of APRIL 
in T-cell-dependent and independent antibody production in human B cells. 105 
Both BAFF and APRIL have previously been shown to stimulate human T cell proliferation 
in presence of suboptimal amounts of anti-CD3 and blocked by TACI-Fc. This has suggested 
that these ligands may actas a costimulatory factor in TCR-mediated activation mediated by 
TACI binding.95•96•89•103•105 However, neither BCMA nor TACI expression was detected in any 
of the naïve or memory subpopulations in this study, making it difficult to explain a 
costimulatory fonction for either of the TNF-like-ligands. A possible explanation would be if 
TACI or BCMA were transiently expressed upon recent anti-CD3 stimulation and then 
rapidly downregulated, thus escaping detection in the experimental conditions of this study. 
The highest levels of APRIL and BAFF transcripts have been found in monocytes and 
macrophages and other APCs. The receptors to these ligands, on the other hand, have 
preferentially been found to be expressed in B cells. This recently discovered ligand-receptor 
pathway has been profoundly implicated in survival, proliferation and differentiation of B 
cells.93 •102 The results of this study provide new insights into other possible roles of this 
signaling system. Additionally, the differential gene expression of the ligands BAFF and 
APRIL on subsets of CD4 T cells indicates that these ligands may be involved in T cell help 
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as well. Further studies are needed to clarify the role of this TNF-like-ligand-receptor system 
in human T cells. 
IL-15Ra 
The results obtained show considerable inter-individual variability m IL-15Ra gene 
expression. Still, certain tendencies emerge: 
@ The IL-l 5Ra gene seems to be generally expressed at slightly higher levels in memory 
T cells than in naïve T cells. 
o The IL-l 5Ra-mRNA levels are most upregulated in the CD8+ T EM and in the CD4+ 
T TEM subsets. 
One can consequently expect both CD4+ and CD8+ memory T cells to express more IL-15Ra 
on their surfaces and generally be more responsive to stimulation through IL-15. This would 
indeed be consistent with numerous studies reporting the requirement of IL-15 for long-term 
maintenance of CD8+ cell memory, in both humans and mice. 53•144• 
Interestingly, in both CD4+ and CD8+ cells, the effector populations (TEM in CD8+ and TrnM 
in CD4+) seem to express the highest transcript levels of IL-15Ra, suggesting that these 
subsets would react most sensitively to the presence of IL-15. This is of importance, because 
it could implicate a different role of IL-15 in humans as compared to mice, where IL-15 has 
been shown to play a crucial role in the expansion potential of central memory populations. 144 
In humans, on the other hand, IL-15 could possibly play a selective role on the effector 
memory populations. This is in agreement with the study of Geginat et al., 141 ' 146 showing that 
the expression of a functional IL-15 receptor and concomitant IL-15 responsiveness are 
associated with differentiation. These characteristics increase from naive subsets to central 
memory and effector memory T cells, without however increasing the expansion potential of 
memory cells as a whole. 
Which role could the IL-15 I IL- l 5Ra interaction have in effector memory T cells? To explain 
this, it is useful to imagine a situation when the survival of effector memory cells is essential, 
such as in persistent viral infections. In healthy individuals, the subset of CD4+ TrnM is very 
small. In the case of progressive HIV-infection, however, this population is expressed in 
higher numbers and is apparently capable of persisting as long as antigen loads are high. 
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Antigen-specific CD4+ TTEM cells are considered to be the most differentiated cells and have 
been shown to consist mostly of IL-2- I IFNt cells, the cells that predominate in the immune 
response to progressive HIV-infection. 14•147•148 Since these cells don't produce the IL-2 
necessary for self-renewal, their higher responsiveness to IL-15 could allow them to survive 
during acute viral infection. On the other hand, in CD8+ cells, the presence of high levels of 
antigen seems to promote the accumulation of the greatest number of antigen-specific cells in 
the T EM population. The skewing of the T TEM subset towards the pre-terminally differentiated 
T EM subset has been proposed as one of the mechanisms of HIV-induced impairment of 
proper CD8+ T cell function. 11 Another possible explanation for the greater number of 
antigen-specific cells within the effector CD8+ population during persisting HIV infection is 
that this could simply occur because of the kinetics in progressive disease which is 
characterized by an extremely high turnover of CD8+ T cells. Consequently, T EM cells would 
accumulate in their effort to replenish the terminally differentiated effector cells - but also 
because of their higher responsiveness to IL-15, giving them an edge over the T TEM subset. 
Indeed, IL-15 is known to be produced endogenously by fibroblasts, keratinocytes, 
endothelial cells, and macrophages. Recalling that effector memory populations lack 
expression of CCR7 and home preferentially to non-lymphoid tissue, one can speculate that 
they might also more readily have access to IL-15 produced by fibroblast-like tissue stroma 
than central memory populations. 
One can thus conclude that, in humans, IL-15 might have arole in driving an efficient effector 
response in viral infections, for bath CD8 and Th 1 responses, by acting as a specific growth 
factor for effector cell populations. If this is the case, the use of IL-15 may be interesting in 
boosting the immune response after vaccination. Quite a few studies support a preferential 
role of IL-15 on effector memory cells. Just recently, the selective expansion of effector 
memory CD8+ T cells by IL-15 has been shown in simian immunodeficiency virus-infected 
macaques. 149 Similarly, the in vitro treatment of PBMCs with IL-15 has been shown to 
enhance IFN-y production of HIV-specific CD8+ T cells, 150 further supporting IL-15's possible 
therapeutic use in persisting viral infections such as chronic HIV-infection. 
One should note that CD4+ memory T cells have previously been reported to be less sensitive 
to IL-15 stimulation. 151 Our results do not contradict this observation, since transcription 
levels between CD4+ and CD8+ cells were not compared at baseline. Also, one might argue 
that the mRNA expression of IL-15Ra may not reflect the effective functional expression of 
the receptor on the cell surface. Either functional or flow-cytometric studies of IL-15Ra 
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surface express10n would be required to further confirm the interpretation of the gene 
expression patterns. 
IL-7Ra 
The data on IL-7Ra gene expression can be briefly interpreted as follows: 
• IL-7Ra-mRNA is generally present in smaller amounts in memory T cells than in 
naïve T cells - except for in the CD8+CD45RA-CCR7+ (TcM) subset where IL-7Ra-
mRNA levels were slightly upregulated. 
Presuming again that gene expression correlates with the expression of a functional receptor, 
these results indicate that, even though memory cells express IL-7Ra and would respond to 
stimulation by IL-7, this cytokine probably preferentially influences naïve T cells - reflected 
by the higher levels oflL-7Ra mRNA in naïve T cells as compared to memory T cells. This is 
consistent with the fact that IL-7 is known to be an important growth factor for naïve T cells 
in both humans and animais. lndeed, naïve T cells have been shown to require the presence of 
IL-7 in an absolute manner for their survival and long-term persistence through peripheral 
homeostatic proliferation, as well as for their development.70•78•152 
Especially CD8+ memory cells seem to downregulate IL-7Ra mRNA levels to a greater 
degree while acquiring a more differentiated effector phenotype. In line with this, recent 
studies have shown a positive correlation between the loss of IL-7R surface expression in 
CD8+ T cells and the activity of HIV-disease in untreated HIV-seropositive patients. After 
treatment by antiretroviral drugs, IL-7R expression in CD8+ cells was found to be 
restored. 153•154 Since our results show that IL-7Ra is preferentially upregulated in the central 
memory subset, the loss of its expression in total CD8+ memory cells might actually reflect a 
loss of central memory type CD8+ cells during untreated HIV disease and a shift towards 
effector memory phenotype cells. Several studies have shown an accumulation of antigen-
specific CD8+ cells within the effector memory subsets (CD45RA-CCRT and 
CD45RA+CCRT phenotypes) during chronic viral infections such as CMV and HIV 
infection. It is noteworthy that the central memory subset of CD8+CD45RA-CCR7+ (TcM) 
cells stands out by showing nearly twice as high IL-7Ra mRNA levels relative to naive CD8+ 
cells. In fact, Ahmed et al. 155 have recently identified a subpopulation of CD8+ cells that 
highly and selectively expresses IL-7Ra as potential memory cell precursors. By adoptively 
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transferring IL-7Ra-high and -low CD8+ cells into mice, they could demonstrate that the IL-
7Ra-high cells gave rise to memory cells that could persist and confer long-term protective 
immunity. One could therefore speculate that, even though IL-7 responsiveness doesn't 
characterize survival of memory cells in general, it may play an important role in selecting a 
defined subset of CD8 memory cells to survive over long periods of time. The fact that these 
IL-7 responsive cells are found to be in the central memory subset makes the suggestion even 
more plausible. 
As regards the expression of the IL-7Ra gene in CD4+ cells, it generally seems to be less 
tightly regulated than in CD8+ cells. Moreover, unlike their CD8+ counterparts, CD4+ 
CD45RA-CCR7+ cells do not selectively upregulate IL-7Ra mRNA levels. Thus, there seems 
to be a differential regulation of responsiveness to IL-7 in the central memory subsets of 
CD4+ and CD8+ T cells. 
Bcl-2 
The results obtained indicate that mRNA levels of the Bcl-2 gene: 
111 are clearly downregulated in all memory CD8+ T cell subsets, relative to the 
expression in naïve CD8+ cells. Lowest levels were present in the CD45RA +CCR T 
population. 
111 are expressed in a more variable manner in memory CD4+ cells with expression levels 
closer to levels in naïve CD4+ cells. 
In this study, Bcl-2 gene expression has been shown to be very consistently downregulated in 
CD8+ memory T cells, as compared to the naïve CD8+ cell population. Additionally, the data 
not only suggests that Bcl-2 expression is generally lower in the memory CD8+ population, 
but also that it is progressively lost from naïve to central memory to effector and terminally 
differentiated effector subsets. These results are in agreement with other studies showing 
decreased Bcl-2 protein expression in memory CD8 subsets. 146 There remains, however, the 
apparently confusing fact that, as a whole, the memory population has to contain long-lived 
cells, yet expresses lower levels of Bcl-2, thus apparently being more susceptible to apoptosis. 
Hence, one could speculate that memory T cells have to be actively "rescued" from cell death 
by extrinsic factors, such as cytokines and growth factors. This is quite clearly the case in 
vitro, where cell death of primed T cells is inhibited by adding exogenous IL-2. One can 
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hypothesize that similar mechanisms may exist in vivo where, amongst possible cytokines 
such as IL-2 and interferon-alpha/beta (IFN-alpha/beta), IL-15 could play an important role in 
protecting effector cells from premature cell death. This is supported by the data of this study 
conceming the expression of IL-15Ra. Indeed, higher levels of specific IL-15 receptor chain 
(IL-15Ra) mRNA were found in the CD8+CD45RA-CCRT subset, suggesting a higher 
responsiveness of the CD8+ effector memo1y population to IL-15. 
Another important observation is that the CD8+ CD45RA-CCR 7+ subset, corresponding to the 
central memory subset, expresses nearly twice as much Bcl-2 than the effector 
subpopulations, suggesting them to be the least apoptosis-susceptible subset out of the 
memory cells. Previous studies have demonstrated the unique ability of the central memory 
population to convert into other phenotypes upon cytokine stimulation, designating them a 
role as precursors of other memory subsets. 141 ' 146 A higher resistance to apoptosis could 
enhance the potential role of T cM cells as a reservoir for other memory cell subsets. 
Surprisingly, the results in the CD4+ population are quite different from the results in CD8+ T 
cells. Besicles being only moderately different from expression levels in naïve CD4+ cells, the 
inter-individual expression levels of Bcl-2 in CD4+ memory cells have been found to be very 
variable in the individuals examined in this study. Of course, a larger study examining a 
greater number of individuals might result in demonstrating certain tendencies of gene 
expression between the CD4+ memory subsets as well. It is nevertheless interesting to note 
that the increased variability in CD4+ memory cells was also observed for the expression of 
the IL-15Ra gene. This was especially apparent in the CD4+ CD45RA-CCR7+ subset, as 
opposed to the concordant expression of Bcl-2 and IL-15Ra genes in the CD8+ CD45RA-
CCR7+ cell population. It is therefore plausible that the susceptibility of CD4+ memory cells 
to cell death is controlled by different pathways than in CD8+ cells. 
Bcl-xL 
The results obtained indicate that: 
• Bcl-xL mRNA levels are upregulated in memory CD8+ cells. Expression levels 
increase with differentiation to a more effector phenotype. 
66 
Discussion 
• In CD4+ cells, Bcl-xL has been found to be moderately higher in all memory CD4+ 
cells, as compared to naïve CD4+ cells. However, only the T EM population showed 
significant upregulation. 
Thus, oppositely to Bcl-2 expression, Bcl-xL gene expression is upregulated in CDS+ memory 
T cells and increases progressively from naïve to central memory to effector and terminally 
differentiated effector subsets. In this context, it is important to emphasize that especially in 
the CDS+ compartment, T EM and T TEM subsets often consist of highly expanded populations, 
resulting from repetitive TCR stimulation through antigen. CD2S ligation, which simulates 
adequate antigen stimulation in vitro, has been shown to induce Bcl-xL production. 156' 157 It 
has been postulated that expanding cells may be protected from apoptosis by this mechanism. 
Hence, effector memory CDS+ cells may be protected against apoptosis, not only through 
enhanced cytokine responsiveness, as discussed above, but also by increased expression of 
anti-apoptotic Bcl-xL. On the other hand, the increase in Bcl-xL may also just reflect the 
greater amount of stimulation and the degree of expansion that effector memory subsets have 
undergone. 
The Bcl-xL expression in CD4+ T cells seems to be similar, even though the results indicate a 
more moderate relative upregulation of Bcl-xL levels in memory CD4+. Thus, it would seem 
that Bcl-xL plays a less important role in memory CD4+ T cell subsets than in the CDS+ T cell 
compartment. One needs to note that, during the development in the thymus, Bcl-xL is known 
to selectively promote maturation of the single positive CDS lineage and that CDS+ cells seem 
to be more Bcl-xL dependant. 117 In contrast to the case of CDS+ cells, however, the highest 
expression levels within CD4+ cells have been observed in the CD45RA-CCRT subset (TEM). 
Therefore, one could argue that the most expanded populations in the CD4+ T cells of healthy 
donors might be localized in the T EM subset. Possibly, this ratio could change in clinical 
settings of high antigen presence, where a shift towards the terminally differentiated subset 
(CD45RA+CCRT population, TTEM) has been observed. 
FLIPs 
The results obtained indicate that, relative to express10n m naïve cells, the FLIPs gene 
express10n: 
• is upregulated in all memory CDS+ T cell subsets. 
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@ is slightly lower in all memory CD4+ cells, as compared to expression in naïve CD4+ 
cells. 
Within the CD8+ T cell population, FLIPs gene expression has been found to be globally 
upregulated in all the memory subsets; increased expression levels, however, predominated in 
the T TEM (CD45RA +CCRT) population. The anti-apoptotic role of FLIPs mainly consists in 
protecting T cells from activation-induced-cell-death (AICD). It does so by intervening in the 
extrinsic, predominantly Fas-mediated pathway of apoptosis by inhibiting caspase-8 
activation and consequent apoptosis. TCR-mediated upregulation of FLIPs has also been 
reported to correlate with FasL-resistance in a proportion of restimulated T cells, indicating it 
may contribute to T-cell survival and memory development in this manner. 124' 158 Indeed, in 
vivo, highly activated cells are placed in the terminally differentiated subset (TEM). This 
population consequently requires the most active protection from AICD. Thus, the 
upregulation of FLIPs found in the TEM subset of CD8+ cells seems to reflect this necessity. 
Why however, were the lowest FLIPs levels found in the EM population? Why should the 
EM subset be more sensitive to AICD? The cells of the EM population reside in the target 
organ of the infection, so that they are likely to receive the most antigen stimulation during 
the immune response. The low levels of FLIPs could enhance their sensitivity to AICD, thus 
controlling their expansion and limiting the number of EM cells. The reduced survival of the 
EM population would then be proportional to the antigen load, allowing the EM population to 
act as an accurate sensor of antigen load. By this mechanism, the EM cell number could drive 
the replenishment of the effector pool from the CM population. 
The situation in CD4+ T cells seems to be quite different since, in contrast to CD8+ cells, 
FLIPs mRNA levels have been found to be preferentially downregulated in all the CD4+ 
memory subsets. This suggests that CD4+ memory T cells might be intrinsically less 
susceptible to Fas-mediated death than CD8+ memory T cells. One should note that, 
analogous to the situation in CD8+ T cells, the EM population seems to express the least 
amount of FLIP, making it the most AICD-sensitive population. The results obtained, 
however, are not as clearly interpretable as in CD8+ cells, since the differences in expression 
levels of naïve and memory cells are qui te small, making it difficult to judge the significance 
of the changes. 
Discussion 
Bad and Bax 
The data for Bad expression in CDS+ T cells demonstrates a high inter-individual variability 
of the expression of this gene in the different memory subsets. Even though mRNA levels are 
present in a more consistent way amongst the CD4+ population of the donors tested, CD4+ 
memory T cells showed only very slight differences of Bad expression levels in comparison 
to naïve CD4+ cells. Thus, it would seem that Bad does not play an impmiant and obvious 
role in regulating the sensitivity to cell death in either CDS+ or CD4+ memory cells. 
Bax gene express10n on the other hand, even though also quite variable amongst the 
individual donors tested, seems to follow clearer tendencies. It is apparently preferentially 
upregulated in CD4+ memory cells, in contrast to a discrete downregulation observed in CDS+ 
memory cells. CD4+ memory cells might therefore be more susceptible to apoptosis mediated 
by Bax than their CDS+ counterparts. 
FasL 
The interactions between Fas and its ligand FasL are supposedly the major mechanisms 
involved in AICD. Naïve human T lymphocytes, however, are known to be insensitive to 
death receptor-induced apoptosis or to AICD. Indeed, activation of naïve T cells results in 
proliferation, cytokine secretion, and effector function. In fact, T cell blasts have been shown 
to start to be sensitive to AICD induction only at day 6 post-activation. 159-161 In this study, the 
resistance of naïve T cells to AICD is reflected by the total absence of FasL expression in 
naive T cells, both for CDS+ T cells and CD4+ T cells, in all the individuals tested. 
In the memory cells of the CDS+ compartment, FasL expression has been shown to increase 
progressively from central memory to terminally differentiated effector cells. Restimulated T 
cells are known to be more sensitive to Fas-mediated apopoptosis. 162 The progressive increase 
of FasL expression in CDS+ memory T cell subsets could thus be interpreted as the result of a 
greater replication history of the effector subsets. Alternatively, one should take into 
consideration another possible interpretation: CDS+ cells are also known as cytotoxic cells 
CTLs) or killer lymphocytes. Their cytotoxic activity is mediated directly by either granzymes 
or perforin, but they can also induce cell death via FasL. The interaction of FasL with Fas, 
expressed on cells other than T cells, enables the induction of immediate cell death in these 
cells through the membrane-bound FasL, expressed on CTLs. The extremely high 
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upregulation of FasL expression could therefore simply be the reflection of the increased 
cytotoxic potential in increasingly effector memory populations. 
The interpretation of the results is less obvious in CD4+ memory T cells, since FasL 
expression was absent in the first two memory subsets (CM and EM). It seems that circulating 
memory CD4+ cells are less susceptible to AICD than their CD8+ counterparts. 
Tob 
The results obtained indicate that Tob expression in CD8+ T cells seems to be lost in the 
process of acquiring a more differentiated state. Since forced Tob expression has previously126 
been shown to inhibit anti-CD3 / anti-CD28-mediated proliferation, the downregulation of 
Tob in vivo should, oppositely, enhance proliferation in response to antigen and co-
stimulation. It is therefore perceivable that activation threshold levels are lowered in memory 
CD8+ T cells by the means of Tob downregulation. This makes sense, as one would expect 
memory CD8+ T cells to react faster and to lower levels of antigen than naïve cells. Inversely, 
constitutive expression of Tob in naïve CD8+ cells could confer peripheral tolerance to 
circulating naïve CD8+ T cells by increasing their activation threshold. This may be a possible 
explanation of the fact that naïve T cells are known to have more restrictive requirements for 
co-stimulation than memory T cells. It is also consistent with the results of Tzachanis et al., 126 
who showed that only TCR-stimulation coupled with appropriate co-stimulation would induce 
a downregulation of Tob, enabling progression of the cell cycle and cell division. 
In this study, as opposed to Tob expression in CD8+ T cells, CD4+ memory cells in general 
and the CD4+ effector-memory populations in particular, have not been shown to 
downregulate Tob mRNA levels. This seems to be in contradiction to the results obtained in 
the above cited study, 126 which had shown a greater downregulation of Tob mRNA in total 
CD4+ cells as compared to CD8+ cells upon stimulation. In their experimental system 
however, the authors measured expression levels between 3 and 24 hours after stimulation. It 
could thus be possible that, upon stimulation, CD4+ T cells transiently downregulate Tob 
expression, which is then regained in circulating memory cells. This would implicate that 
CD4+ T cells require efficient co-stimulation at any stage of differentiation, showing no 
significant difference of the activation thresholds between subsets of memory CD4+ T cells, 
or between memory and naïve CD4+ T cells. Again, this does not correspond well with the 
known fact that memory CD4+CCR7+ and CD4+CCRT, to an even greater extent, show 
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enhanced responsiveness to T-cell receptor triggering.7 Hence, how can activation thresholds 
be modulated without affecting Tob mRNA levels? The inhibitory effect of Tob has been 
shown to be inactivated by phosphorylation through Erkl and Erk2. 129 One could therefore 
also imagine that in CD4+ cells, in contrast to the case of CD8+ cells, Tob activity may be 
regulated not by lowering expression levels, but by phosphorylation instead. This is supported 
by the fact that ERK MAP kinases are essential for TCR-induced responses. 163 Of course, an 
alternative pathway, not implicating Tob at all, may also be involved. 
Results in CDS+ memory cells 
When looking at the gene expression pattern in the CD8+ T cell compartment as a whole, the 
more cytotoxic, directly effector CD8+ memory cells, e.g. the T EM and T TEM subsets, seem to 
be much more susceptible to cell death than the central memory subset. This is reflected not 
only in their extremely prominent upregulation of FasL, but also in the downregulation of 
protective factors such as Bcl-2, IL-7Ra, BAFF-R, and APRIL. Their decreased expression of 
Tob also indirectly increases the AICD susceptibility by lowering the activation threshold. On 
the other hand, they are actively protected against cell death by higher levels of the anti-
apoptotic factors Bcl-xL and FLIP, as well as possibly through a higher responsiveness to IL-
15. 
Thus, generally speaking, the results of this study indicate that in CD8+ T cells there is a 
greater sensitivity to cell death in the CCR T effector memory subsets (T EM and T TEM), as 
compared to the CCR 7+ population consisting of naïve and central memory (T cM) CD8+ T 
cells. In the CCR T cells, re-encounter with antigen would therefore not only induce execution 
of effector functions, but also rapidly cause apoptosis. CD8+ CCR T cells have been shown to 
mediate particularly effective effector function through IFNy and also express high levels of 
perforin. Why then should the most effective cells die? One possible explanation is that, in 
viral infections, the cells that accumulate in the target organ of the infection are mostly of the 
TTEM cell-type, reflecting the capacity of CCRT cells to preferentially home to non-lymphoïd 
tissue. Upon re-exposure, one can imagine that the already present T TEM cells would rapidly 
intervene and their frequency in situ might be sufficiently elevated to mediate an effective 
immune response without requiring cell proliferation. Additionally, AICD in T cells in vivo 
has been proposed to limit the expansion of an immune response by eliminating effector cells 
that are no longer needed. Indeed, after antigen or pathogens have been eliminated from the 
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organism, these T cells are potentially dangerous because of their potent effector functions 
and low activation requirements. Hence, their increased susceptibility to death is also 
extremely important to counterbalance these traits, which would otherwise lead to 
uncontrolled cytotoxicity, harmful to the host. Another influence on the results may be the 
fact that the terminally differentiated effector population (T TEM) might be the population 
containing the most in vivo expanded clones in any individual. The sensitivity to cell death 
would then simply be a reflection of the cell age, e.g. the number of prior cell divisions. This 
was shown in previous reports stating that, in the CD8+ compartment, the loss of CD28 
identifies a subset of antigen-experienced T cells with high cytotoxic potential and reduced 
proliferative capacity, and which frequently contains in vivo-expanded clones in the elderly or 
in human immunodeficiency virus (HIV-) infected individuals. 164-166 
Apart from showing a possible linear differentiation pattern in CD8+ T cells with progressive 
susceptibility to apoptosis in the CCR T memory subsets, there seems to be a differential 
responsiveness to cytokines amongst the memory subsets. Cytokines may therefore play a 
crucial role in modulating the function of the distinct memory subsets. Thus, the upregulation 
of IL-7Ra on the central memory subset of CD8+ T cells may confer a selective survival 
signal to this population, making them the true memory cells of the immune response. 
Results in CD4+ memory cells 
One of the most notable features of the gene expression patterns observed in CD4+ cells has 
been the greater inter-individual variability, as compared to CD8+ T cells. Secondly, the 
differences in expression levels of memory and naïve cells were found to be much less 
contrasted than in the CD8+ compartment. One can conclude that gene expression levels 
between circulating memory cells and naïve cells are quite stable. One might argue that CD4+ 
cells possibly do not control their survival pathways at the gene expression level, but that they 
regulate it though activation and inactivation at a protein level. This may of course be true for 
individual pathways, but it does not explain the variability in expression between the donors. 
Another possible explanation is that CD4+ cells modify their gene expression profiles in a 
much more transient manner, regaining stable expression levels in a resting, circulating state. 
This option would need further clarification by analyzing gene expression in recently primed 
CD4 cells and combining it with a chronologically progressive follow-up of the gene profile. 
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CD4+ memory T cells have been shown to present less downregulation of the survival factor 
IL-7Ra and the anti-apoptotic factors Bcl-2, as also lower levels of FasL mRNA, suggesting 
them to be generally less sensitive to cell-death than their CD8+ counterparts 
Differences between CD4+ and CDS+ memory cells 
Firstly, the point to be emphasized is that there seems to be a considerable difference between 
the CD4+ and CD8+ compartments of memory T cells. This is interesting in itself since even 
though CD4+ and CD8+ T cells have different roles in the immune response, one could have 
imagined that the conditions allowing them to maintain memory traits would be quite similar. 
On the whole, CD4+ memory T cells have been shown to be less sensitive to activation-
induced cell death (less downregulation of Bcl-2, lower levels of FasL mRNA). This mirrors 
the inherent difference in the functional roles of CD8+ and CD4+ cells. CD4+ T cells have a 
"helper" role, as opposed to the "killer" role of CD8+ lymphocytes. One could imagine that 
the heterogeneity in survival and apoptosis gene expression patterns observed between 
CD8+ and CD4+ T cells may also reoccur on the level of their differentiation pathways. In the 
CD8+ compartment, a linear differentiation pattern makes sense. It associates replication 
history to differentiation, and differentiation to increased cell death susceptibility. The rather 
straight-forward role of CD8+ T cells is compatible with this; they differentiate to kill and, 
once they have executed their mission, their function is superfluous. The role of CD4+ 
memory T cells is more complex. Their effector role consists in communicating with other 
components of the immune system and enhancing the overall effectiveness of the immune 
response. Moreover, the effector CD4+ T cells are quite heterogeneous, consisting of Th-1 
cells with an IFNy-secreting profile, IL-4 secreting Th-2 cells and the immunosuppressive 
CD4+CD25high Treg cells amongst others. Only a more complex differentiation pattern with 
multiple checkpoints would enable the generation of such a heterogeneous population. The 
overall increased relative resistance to activation-induced cell death could thus guarantee a 
higher plasticity in the differentiation of memory CD4+ cells. 
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8 CONCLUSIONS 
By separating T cells into different subsets according to the expression of CD45RA and their 
lymph-homing ability as mediated by expression of CCR 7, human T cells can be separated 
into 4 subsets compromised of naïve cells, central memory cells, effector memory and 
terminally differentiated effector memory cells. In this study, the differential sensitivity to 
survival and cell death of these subsets has been studied by analysis of the gene expression 
pattern of a selection of pertinent genes. The data collected shows that CD4+ memory T cells 
and CDS+ human memory T cells regulate genes implicated in survival and apoptosis in 
different ways. The CDS+ T cell compartment preferentially showed progressive susceptibility 
to cell death from naïve and central memory (CCR7+) subsets to effector and terminally 
differentiated effector (CCRT) subsets. The expression of genes involved in protection from 
apoptosis (Bcl-2), as well as of genes implicated in survival pathways (IL-7R, APRIL, BAFF-
R), is progressively lost. In contrast, expression of pro-apoptotic factors such as Bax and FasL 
is gradually increased (Figure 7). 
Importantly, the CDS+ CD45RA- CCR7+ central memory subset was shown to selectively 
upregulate the expression of the functional IL-7 receptor (IL-7Ra), proposing the enhanced 
responsiveness to IL-7 as a selection bias for long-term memory. On the other hand, IL-15Ra 
expression was selectively increased in the CDS+ CD45RA-CCR T effector memory subset, 
suggesting a role for IL-15 in enhancing long-term effector responses. 
From this study, it is clear that human T cell memory subsets depend on many factors that 
influence their ability to survive, on the one hand, and their susceptibility to cell death on the 
other. The balance of these interactions seems to influence their long-term survival. The 
differences observed between the gene expression patterns of CD4+ and CDS+ cells speak in 
favour of distinct memory cell differentiation patterns in these two T lymphocyte 
compartments. 
To further unravel the interactions of survival and death signals in memory T cell subsets is 
crucial to our understanding of the secondary immune response and of adaptive cell-mediated 
immunity in general. It is thus central to our comprehension of the natural evolution of 
infectious diseases, such as acute infection and resolution versus establishment of chronic 
disease. As such, it will help discovering mechanisms of inducing and enhancing long-term 
immunological memory, which is essential to the field of vaccine development. 
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FIGURE 7 
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Expression of survival and pro-apoptotic genes in CDS memory subsets. Genes 
potentially mediating survival enhancing mechanisms (e.g. BAFF-Receptor, IL-7Ra 
and Bcl-2) are expressed in higher levels in central memory T cells (TcM). Pro-
apoptotic genes ( e.g. Bax and Fas-Ligand) are suppressed in this population, but 
expressed at higher levels in the effector populations (T EM and T TEM), implying a 
higher susceptibility to apoptosis. 
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9 PERSPECTIVES 
The present study has reported tendencies in gene expression patterns of memory T cells of 
healthy individuals. Considering the great inter-individual heterogeneity in gene expression, a 
larger study including more individuals should be performed to evaluate the significance of 
the differences observed. 
Additionally, it would be of great interest to follow this up with studies on antigen-specific 
memory T cells. Extremely little is lmown of the relative sensitivity to apoptosis in vivo of 
these cells. This would be possible using the same experimental design which combines flow-
cytometric sorting with a sensitive RT-PCR assay. Indeed, this methodology has allowed the 
use of extremely few cells per subset and to evaluate a fairly large gene panel. By further 
confining the gene panel to maybe just four genes per run, this approach could allow the 
investigation of gene expression in even more restricted subsets, such as tetramer positive or 
cytokine positive T cells from CMV, EBV or HIV-infected individuals. This could provide 
insights into the specific genetic pattern of "real" antigen-specific memory T cells. It would be 
interesting to lmow, for example, as to whether in HIV (where the antigen-specific CD8 
memory compartment seems to be skewed) a different expression of apoptosis genes could 
account for the skewing. 
As mentioned earlier, experimental evidence at the protein level is required in order to 
investigate the possible functional importance of the genetic pattern observed. In this context, 
it would be particularly interesting to further examine the expression of transcripts of BAFF, 
APRIL and their receptors in human T cells. Do T cells secrete APRIL and BAFF, or do they 
express them as membrane-bound proteins on their surface? Do BAFF-R mRNA transcript 
levels in T cells correlate with a surface expression of BAFF-R? If so, how is the expression 
induced, which are the cells which will provide the stimulus, what are the consequences of 
ligand-receptor interactions, and which are the downstream signaling pathways implicated? 
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